<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.mdpi.com/journal/cancers');</script>

        <script> var body_html = '<body> <div > <div > <div > <a > <h2>25th Anniversary</h2> </a> <a > <h2>Journals</h2> </a> <div > <div > <h2>Information</h2> </div> <div > <div > <div > <a >For Authors</a> <a >For Reviewers</a> <a >For Editors</a> <a >For Librarians</a> <a >For Publishers</a> <a >For Societies</a> </div> <div > <a >Article Processing Charges</a> <a >Open Access Policy</a> <a >Institutional Open Access Program</a> <a >Editorial Process</a> <a >Awards</a> <a >Research and Publication Ethics</a> </div> </div> </div> </div> <a > <h2>Author Services</h2> </a> <div > <div > <h2>Initiatives</h2> </div> <div > <div > <div > <a >Sciforum</a> <a >MDPI Books</a> <a >Preprints</a> <a >Scilit</a> <a >SciProfiles</a> <a >Encyclopedia</a> <a >JAMS</a> <a >Proceedings Series</a> </div> </div> </div> </div> <a > <h2>About</h2> </a> </div> <div > <a >Sign In / Sign Up</a> </div> </div> </div> <div > <h2 >Notice</h2> <a > <i >clear</i> </a> </div> <div > <div > <div > <h2 >Notice</h2> <p> You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader. </p> </div> </div> <div > <div > <a >Continue</a> <a >Cancel</a> </div> </div> <a > <i >clear</i> </a> </div> <div > <p> All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. </p> </div> <div > <p> Feature Papers represent the most advanced research with significant potential for high impact in the field. Feature Papers are submitted upon individual invitation or recommendation by the scientific editors and undergo peer review prior to publication. </p> <p> The Feature Paper can be either an original research article, a substantial novel research study that often involves several techniques or approaches, or a comprehensive review paper with concise and precise updates on the latest progress in the field that systematically reviews the most exciting advances in scientific literature. This type of paper provides an outlook on future directions of research or possible applications. </p> </div> <div > <p> Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to authors, or important in this field. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal. </p> </div> <div > <div >  </div> <section > <header> <div > <div > <div > <ul> <li > <a >25th Anniversary</a> </li> <li > <a >Journals</a> </li> <li > <a >Information</a> <ul > <li> <div > <div > <ul> <li> <a >For Authors</a> </li> <li> <a >For Reviewers</a> </li> <li> <a >For Editors</a> </li> <li> <a >For Librarians</a> </li> <li> <a >For Publishers</a> </li> <li> <a >For Societies</a> </li> </ul> </div> <div > <ul> <li> <a >Article Processing Charges</a> </li> <li> <a >Open Access Policy</a> </li> <li> <a >Institutional Open Access Program</a> </li> <li> <a >Editorial Process</a> </li> <li> <a >Awards</a> </li> <li> <a >Research and Publication Ethics</a> </li> </ul> </div> </div> </li> </ul> </li> <li > <a >Author Services</a> </li> <li > <a >Initiatives</a> <ul > <li> <div > <div > <ul> <li> <a > Sciforum </a> </li> <li> <a > MDPI Books </a> </li> <li> <a > Preprints </a> </li> <li> <a > Scilit </a> </li> <li> <a > SciProfiles </a> </li> <li> <a > Encyclopedia </a> </li> <li> <a > JAMS </a> </li> <li> <a > Proceedings Series </a> </li> </ul> </div> </div> </li> </ul> </li> <li > <a >About</a> </li> </ul> </div> <div > <div> <a >Sign In / Sign Up</a> <a >Submit</a> </div> </div> </div> </div> <div > <div > <div > <div > <a > Covered in: PubMed </a> </div></div> <div > <div > <a > IMPACTFACTOR 6.639 </a> </div> </div> </div> <div > Journals </div> <div > Cancers </div> </div> </header> <div > <div > <div > <div > <div > <ul > <li> <a > <div > ‘Palliative-D’—A Randomized Controlled Trial on the Effects of Vitamin D in Palliative Cancer Care </div> </a> </li> <li > <a > <div > Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs </div> </a> </li> <li > <a > <div > Epigenetic Immunomodulators to Enhance Immunotherapy </div> </a> </li> </ul> </div> </div> <div > <div > <h2 >Journal Description</h2> </div> <div > <div > <h1> Cancers </h1> <div > Cancers is a <a >peer-reviewed</a>, open access journal of oncology published semimonthly online by MDPI. The <a >Irish Association for Cancer Research (IACR)</a>, <a >Signal Transduction Society (STS)</a> and <a >Spanish Association for Cancer Research (ASEICA)</a> are affiliated with Cancers and their members receive a discount on the article processing charges. <ul> <li>Open Access— free for readers, with <a >article processing charges (APC)</a> paid by authors or their institutions.</li> <li>High Visibility: indexed within <a >Scopus</a>, <a >SCIE (Web of Science)</a>, <a >PubMed</a>, <a >PMC</a>, <a >Embase</a>, <a >CAPlus / SciFinder</a>, and many <a >other databases</a>.</li> <li>Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q2 (Oncology)</li> <li>Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 3.7 days (median values for papers published in this journal in the first half of 2021).</li> <li>Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.</li> <li>Sections: published in 14 topical sections. </li> <li>Companion journals for Cancers include: <a >Radiation</a> and <a >Onco</a>.</li> </ul> </div> <div > Impact Factor: 6.639 (2020) ; 5-Year Impact Factor: 6.999 (2020) </div> <div> <a > <i >subject</i> Imprint Information </a> <a > <i >get_app</i> Journal Flyer </a> <a > Open Access </a> ISSN: 2072-6694 </div> </div> </div> </div> <div > <div > <h2 >Latest Articles</h2> </div> <div > <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: <a >Abstract Page</a> <a >Full-Text HTML</a> </div> </div> <div >Open AccessReview</div> Therapeutic Targets of KRAS in Colorectal Cancer <div > by <span ><div >Shafia Rahman</div>, </span><span ><div >Shimon Garrel</div>, </span><span ><div >Michael Gerber</div>, </span><span ><div >Radhashree Maitra</div> and </span><span ><div >Sanjay Goel</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6233; https://doi.org/10.3390/cancers13246233 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor <i>KRAS</i> mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also [...] Read more. </div> <div > Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor <i>KRAS</i> mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with <i>KRAS</i>-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting <i>KRAS</i>- mutant CRC, while reviewing and elaborating on the discovery and physiology of <i>KRAS.</i> Full article </div> </div> <div > (This article belongs to the Special Issue Targeting KRAS: Elucidating Mechanisms of Sensitivity and Resistance) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 2249 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> The Antiviral Drug Efavirenz in Breast Cancer Stem Cell Therapy <div > by <span ><div >Pey-Tsyr Chiou</div>, </span><span ><div >Stephen Ohms</div>, </span><span ><div >Philip G. Board</div>, </span><span ><div >Jane E. Dahlstrom</div>, </span><span ><div >Danny Rangasamy</div> and </span><span ><div >Marco G. Casarotto</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6232; https://doi.org/10.3390/cancers13246232 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > Although many breast cancer therapies show initial success in the treatment of the primary tumour, they often fail to eliminate a sub-population of cells known as cancer stem cells (CSCs). These cells are recognised for their self-renewal properties and for their capacity for [...] Read more. </div> <div > Although many breast cancer therapies show initial success in the treatment of the primary tumour, they often fail to eliminate a sub-population of cells known as cancer stem cells (CSCs). These cells are recognised for their self-renewal properties and for their capacity for differentiation often leading to chemo/radio-resistance. The antiviral drug Efavirenz has been shown to be effective in eliminating triple-negative breast cancer cells, and here we examine its effect on breast CSCs. The effects of Efavirenz on CSCs for several breast cancer cell lines were investigated by examining cellular changes upon drug treatment, including CSC numbers, morphology, RNA/microRNA expression and levels of epithelial/mesenchymal CSC subtypes. Efavirenz treatment resulted in a decrease in the size and number of tumorspheres and a reduction in epithelial-type CSC levels, but an increase in mesenchymal-type CSCs. Efavirenz caused upregulation of several CSC-related genes as well as <i>miR-21</i>, a CSC marker and <i>miR-182</i>, a CSC suppressor gene. We conclude that Efavirenz alters the phenotype and expression of key genes in breast CSCs, which has important potential therapeutic implications. Full article </div> </div> <div > (This article belongs to the Special Issue Understanding and Modelling Metabolic Reprogramming in Breast Cancer) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessReview</div> Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment <div > by <span ><div >Racheal Louise Johnson</div>, </span><span ><div >Michele Cummings</div>, </span><span ><div >Amudha Thangavelu</div>, </span><span ><div >Georgios Theophilou</div>, </span><span ><div >Diederick de Jong</div> and </span><span ><div >Nicolas Michel Orsi</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6231; https://doi.org/10.3390/cancers13246231 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > A lack of explicit early clinical signs and effective screening measures mean that ovarian cancer (OC) often presents as advanced, incurable disease. While conventional treatment combines maximal cytoreductive surgery and platinum-based chemotherapy, patients frequently develop chemoresistance and disease recurrence. The clinical application of [...] Read more. </div> <div > A lack of explicit early clinical signs and effective screening measures mean that ovarian cancer (OC) often presents as advanced, incurable disease. While conventional treatment combines maximal cytoreductive surgery and platinum-based chemotherapy, patients frequently develop chemoresistance and disease recurrence. The clinical application of immune checkpoint blockade (ICB) aims to restore anti-cancer T-cell function in the tumour microenvironment (TME). Disappointingly, even though tumour infiltrating lymphocytes are associated with superior survival in OC, ICB has offered limited therapeutic benefits. Herein, we discuss specific TME features that prevent ICB from reaching its full potential, focussing in particular on the challenges created by immune, genomic and metabolic alterations. We explore both recent and current therapeutic strategies aiming to overcome these hurdles, including the synergistic effect of combination treatments with immune-based strategies and review the status quo of current clinical trials aiming to maximise the success of immunotherapy in OC. Full article </div> </div> <div > (This article belongs to the Special Issue Immunotherapy in Ovarian Cancer) </div> ►▼ Show Figures <div ><div ><div ><p>Graphical abstract</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse <div > by <span ><div >Costanza Chiapponi</div>, </span><span ><div >Milan J. M. Hartmann</div>, </span><span ><div >Matthias Schmidt</div>, </span><span ><div >Michael Faust</div>, </span><span ><div >Anne M. Schultheis</div>, </span><span ><div >Christiane J. Bruns</div> and </span><span ><div >Hakan Alakus</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6230; https://doi.org/10.3390/cancers13246230 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > Compared to its more common counterpart papillary thyroid cancer (PTC), follicular thyroid cancer (FTC) has a less favorable outcome, due to its higher incidence of distant metastases and advanced stages at diagnosis. Despite radioiodine (RAI) avidity, metastatic FTC often progresses after radioiodine treatment [...] Read more. </div> <div > Compared to its more common counterpart papillary thyroid cancer (PTC), follicular thyroid cancer (FTC) has a less favorable outcome, due to its higher incidence of distant metastases and advanced stages at diagnosis. Despite radioiodine (RAI) avidity, metastatic FTC often progresses after radioiodine treatment (RAIT). We aimed at evaluating the indications and outcomes of surgery for cervical relapse of radioiodine refractory FTC. Patients receiving RAIT between 2005 and 2015 at the University Hospital of Cologne, Germany, were screened. Patients with FTC were identified. Demographics, clinic-pathologic characteristics, treatment, and outcome of patients diagnosed with RAI refractory FTC, who underwent cervical surgery in the course of disease, were analyzed. FTC accounted for 8.8% of all thyroid carcinomas undergoing RAIT. In 35.2% of FTC patients, disease persisted or recurred despite a cumulative mean RAI activity of 18.7 GBq ± 11.6 (follow-up 83.5 ± 56.7 months). Distant metastases were diagnosed in 75% of these patients, as bone (57.6%), lung (54.6%), and liver metastases (12.1%). Cervical relapse occurred in 63.6% of these patients and was treated in 57.1% with surgery with, and without, external beam radiation therapy (EBRT). Despite surgery and EBRT, in 75% of patients, cervical relapse recurred again. In conclusion, surgery for cervical radioiodine refractory FTC relapse is often performed in metastatic setting. With and without EBRT, cure is rare, although metastases can appear radioiodine avid. Early biological marker and systemic treatments for these patients are still needed. Full article </div> </div> <div > (This article belongs to the Special Issue Updates in Thyroid Cancer Surgery) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessReview</div> Cancer Therapy Targeting CD47/SIRPα <div > by <span ><div >Nazli Dizman</div> and </span><span ><div >Elizabeth I. Buchbinder</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6229; https://doi.org/10.3390/cancers13246229 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > In the past decade, the field of cancer immunotherapy has rapidly advanced, establishing a crucial role for immune checkpoint blockers in the treatment of a variety of cancer types. In parallel with these remarkable clinical developments, further efforts have focused on ways of [...] Read more. </div> <div > In the past decade, the field of cancer immunotherapy has rapidly advanced, establishing a crucial role for immune checkpoint blockers in the treatment of a variety of cancer types. In parallel with these remarkable clinical developments, further efforts have focused on ways of unleashing adaptive immune responses against cancer. CD47, a cell surface molecule overexpressed by several cancer types that facilitates immune escape from macrophages, dendritic cells and natural killer cells, and its ligand SIRPα, have emerged as potential therapeutic targets. A number of agents directed to CD47/SIRPα have been developed and demonstrated preclinical activity. Early phase clinical trials are investigating CD47/SIRPα directed agents with available data, suggesting safety and preliminary activity. Herein, we provide an overview of the mechanistic rationale of targeting CD47/SIRPα axis and associated clinical evidence. Full article </div> </div> <div > (This article belongs to the Special Issue Targeting Innate Immunity to Treat Cancer) </div> ►▼ Show Figures <div ><div ><div ><p>Graphical abstract</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessReview</div> Multicellular Effects of STAT3 in Non-Small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities <div > by <span ><div >Sagun Parakh</div>, </span><span ><div >Matthias Ernst</div> and </span><span ><div >Ashleigh R. Poh</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6228; https://doi.org/10.3390/cancers13246228 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of lung cancer cases. Aberrant activation of the Signal Transducer and Activator of Transcription 3 (STAT3) is frequently observed in NSCLC and is associated with a [...] Read more. </div> <div > Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of lung cancer cases. Aberrant activation of the Signal Transducer and Activator of Transcription 3 (STAT3) is frequently observed in NSCLC and is associated with a poor prognosis. Pre-clinical studies have revealed an unequivocal role for tumor cell-intrinsic and extrinsic STAT3 signaling in NSCLC by promoting angiogenesis, cell survival, cancer cell stemness, drug resistance, and evasion of anti-tumor immunity. Several STAT3-targeting strategies have also been investigated in pre-clinical models, and include preventing upstream receptor/ligand interactions, promoting the degradation of STAT3 mRNA, and interfering with STAT3 DNA binding. In this review, we discuss the molecular and immunological mechanisms by which persistent STAT3 activation promotes NSCLC development, and the utility of STAT3 as a prognostic and predictive biomarker in NSCLC. We also provide a comprehensive update of STAT3-targeting therapies that are currently undergoing clinical evaluation, and discuss the challenges associated with these treatment modalities in human patients. Full article </div> </div> <div > (This article belongs to the Special Issue Multicellular Effects of STAT3 in the Tumour Microenvironment) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessReview</div> T Cell Aging in Patients with Colorectal Cancer—What Do We Know So Far? <div > by <span ><div >Oana-Maria Thoma</div>, </span><span ><div >Markus F. Neurath</div> and </span><span ><div >Maximilian J. Waldner</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6227; https://doi.org/10.3390/cancers13246227 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > Colorectal cancer (CRC) continues to be one of the most frequently diagnosed types of cancers in the world. CRC is considered to affect mostly elderly patients, and the number of diagnosed cases increases with age. Even though general screening improves outcomes, the overall [...] Read more. </div> <div > Colorectal cancer (CRC) continues to be one of the most frequently diagnosed types of cancers in the world. CRC is considered to affect mostly elderly patients, and the number of diagnosed cases increases with age. Even though general screening improves outcomes, the overall survival and recurrence-free CRC rates in aged individuals are highly dependent on their history of comorbidities. Furthermore, aging is also known to alter the immune system, and especially the adaptive immune T cells. Many studies have emphasized the importance of T cell responses to CRC. Therefore, understanding how age-related changes affect the outcome in CRC patients is crucial. This review focuses on what is so far known about age-related T cell dysfunction in elderly patients with colorectal cancer and how aged T cells can mediate its development. Last, this study describes the advances in basic animal models that have potential to be used to elucidate the role of aged T cells in CRC. Full article </div> </div> <div > (This article belongs to the Special Issue Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessReview</div> Insights into the Role of Matrix Metalloproteinases in Precancerous Conditions and in Colorectal Cancer <div > by <span ><div >Zahra Pezeshkian</div>, </span><span ><div >Stefania Nobili</div>, </span><span ><div >Noshad Peyravian</div>, </span><span ><div >Bahador Shojaee</div>, </span><span ><div >Haniye Nazari</div>, </span><span ><div >Hiva Soleimani</div>, </span><span ><div >Hamid Asadzadeh-Aghdaei</div>, </span><span ><div >Maziar Ashrafian Bonab</div>, </span><span ><div >Ehsan Nazemalhosseini-Mojarad</div> and </span><span ><div >Enrico Mini</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6226; https://doi.org/10.3390/cancers13246226 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Colorectal cancer (CRC) is the third and second cancer for incidence and mortality worldwide, respectively, and is becoming prevalent in developing countries. Most CRCs derive from polyps, especially adenomatous polyps, which can gradually transform into CRC. The family of Matrix Metalloproteinases (MMPs) plays [...] Read more. </div> <div > Colorectal cancer (CRC) is the third and second cancer for incidence and mortality worldwide, respectively, and is becoming prevalent in developing countries. Most CRCs derive from polyps, especially adenomatous polyps, which can gradually transform into CRC. The family of Matrix Metalloproteinases (MMPs) plays a critical role in the initiation and progression of CRC. Prominent MMPs, including MMP-1, MMP-2, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, MMP-14, and MMP-21, have been detected in CRC patients, and the expression of most of them correlates with a poor prognosis. Moreover, many studies have explored the inhibition of MMPs and targeted therapy for CRC, but there is not enough information about the role of MMPs in polyp malignancy. In this review, we discuss the role of MMPs in colorectal cancer and its pathogenesis Full article </div> </div> <div > (This article belongs to the Special Issue Colorectal Cancers: From Present Problems to Future Solutions) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 786 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessArticle</div> Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients <div > by <span ><div >Du-Bois Asante</div>, </span><span ><div >Michael Morici</div>, </span><span ><div >Ganendra R. K. A. Mohan</div>, </span><span ><div >Emmanuel Acheampong</div>, </span><span ><div >Isaac Spencer</div>, </span><span ><div >Weitao Lin</div>, </span><span ><div >Paula van Miert</div>, </span><span ><div >Samantha Gibson</div>, </span><span ><div >Aaron B. Beasley</div>, </span><span ><div >Melanie Ziman</div>, </span><span ><div >Leslie Calapre</div>, </span><span ><div >Tarek M. Meniawy</div> and </span><span ><div >Elin S. Gray</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6225; https://doi.org/10.3390/cancers13246225 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Detection of ovarian cancer (OC) circulating tumour cells (CTCs) is primarily based on targeting epithelial markers, thus failing to detect mesenchymal tumour cells. More importantly, the immune checkpoint inhibitor marker PD-L1 has not been demonstrated on CTCs from OC patients. An antibody staining [...] Read more. </div> <div > Detection of ovarian cancer (OC) circulating tumour cells (CTCs) is primarily based on targeting epithelial markers, thus failing to detect mesenchymal tumour cells. More importantly, the immune checkpoint inhibitor marker PD-L1 has not been demonstrated on CTCs from OC patients. An antibody staining protocol was developed and tested using SKOV-3 and OVCA432 OC cell lines. We targeted epithelial (cytokeratin (CK) and EpCAM), mesenchymal (vimentin), and OC-specific (PAX8) markers for detection of CTCs, and CD45/16 and CD31 were used for the exclusion of white blood and vascular endothelial cells, respectively. PD-L1 was used for CTC characterisation. CTCs were enriched using the Parsortix<sup>TM</sup> system from 16 OC patients. Results revealed the presence of CTCs in 10 (63%) cases. CTCs were heterogeneous, with 113/157 (72%) cells positive for CK/EpCAM (epithelial marker), 58/157 (37%) positive for vimentin (mesenchymal marker), and 17/157 (11%) for both (hybrid). PAX8 was only found in 11/157 (7%) CTCs. In addition, 62/157 (39%) CTCs were positive for PD-L1. Positivity for PD-L1 was significantly associated with the hybrid phenotype when compared with the epithelial (<i>p </i>= 0.007) and mesenchymal (<i>p </i>= 0.0009) expressing CTCs. Characterisation of CTC phenotypes in relation to clinical outcomes is needed to provide insight into the role that epithelial to mesenchymal plasticity plays in OC and its relationship with PD-L1. Full article </div> </div> <div > (This article belongs to the Topic Advances in Ovarian Cancer Research: From Biology to Therapeutics) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 2530 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessArticle</div> Mapping the Melanoma Plasma Proteome (MPP) Using Single-Shot Proteomics Interfaced with the WiMT Database <div > by <span ><div >Natália Almeida</div>, </span><span ><div >Jimmy Rodriguez</div>, </span><span ><div >Indira Pla Parada</div>, </span><span ><div >Yasset Perez-Riverol</div>, </span><span ><div >Nicole Woldmar</div>, </span><span ><div >Yonghyo Kim</div>, </span><span ><div >Henriett Oskolas</div>, </span><span ><div >Lazaro Betancourt</div>, </span><span ><div >Jeovanis Gil Valdés</div>, </span><span ><div >K. Barbara Sahlin</div>, </span><span ><div >Luciana Pizzatti</div>, </span><span ><div >A. Marcell Szasz</div>, </span><span ><div >Sarolta Kárpáti</div>, </span><span ><div >Roger Appelqvist</div>, </span><span ><div >Johan Malm</div>, </span><span ><div >Gilberto B. Domont</div>, </span><span ><div >Fábio C. S. Nogueira</div>, </span><span ><div >György Marko-Varga</div> and </span><span ><div >Aniel Sanchez</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6224; https://doi.org/10.3390/cancers13246224 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Plasma analysis by mass spectrometry-based proteomics remains a challenge due to its large dynamic range of 10 orders in magnitude. We created a methodology for protein identification known as Wise MS Transfer (WiMT). Melanoma plasma samples from biobank archives were directly analyzed using [...] Read more. </div> <div > Plasma analysis by mass spectrometry-based proteomics remains a challenge due to its large dynamic range of 10 orders in magnitude. We created a methodology for protein identification known as Wise MS Transfer (WiMT). Melanoma plasma samples from biobank archives were directly analyzed using simple sample preparation. WiMT is based on MS1 features between several MS runs together with custom protein databases for ID generation. This entails a multi-level dynamic protein database with different immunodepletion strategies by applying single-shot proteomics. The highest number of melanoma plasma proteins from undepleted and unfractionated plasma was reported, mapping &gt;1200 proteins from &gt;10,000 protein sequences with confirmed significance scoring. Of these, more than 660 proteins were annotated by WiMT from the resulting ~5800 protein sequences. We could verify 4000 proteins by MS1t analysis from HeLA extracts. The WiMT platform provided an output in which 12 previously well-known candidate markers were identified. We also identified low-abundant proteins with functions related to (i) cell signaling, (ii) immune system regulators, and (iii) proteins regulating folding, sorting, and degradation, as well as (iv) vesicular transport proteins. WiMT holds the potential for use in large-scale screening studies with simple sample preparation, and can lead to the discovery of novel proteins with key melanoma disease functions. Full article </div> </div> <div > (This article belongs to the Special Issue Metastatic Progression of Human Melanoma) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessReview</div> Function-Preserving Gastrectomy for Early Gastric Cancer <div > by <span ><div >Yoshihiro Hiramatsu</div>, </span><span ><div >Hirotoshi Kikuchi</div> and </span><span ><div >Hiroya Takeuchi</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6223; https://doi.org/10.3390/cancers13246223 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Recently, minimally invasive (endoscopic or laparoscopic) treatment for early gastric cancer (EGC) has been widely accepted. However, a standard gastrectomy with radical lymphadenectomy is generally performed in patients with EGC who have no indications for endoscopic resection, and postgastrectomy dysfunction is one of [...] Read more. </div> <div > Recently, minimally invasive (endoscopic or laparoscopic) treatment for early gastric cancer (EGC) has been widely accepted. However, a standard gastrectomy with radical lymphadenectomy is generally performed in patients with EGC who have no indications for endoscopic resection, and postgastrectomy dysfunction is one of the problems of standard gastrectomy. Function-preserving gastrectomy, such as proximal gastrectomy and pylorus-preserving gastrectomy, can be considered when attempting to preserve the patient’s quality of life (QOL) postoperatively. In addition, sentinel node navigation surgery for EGC has been applied in clinical practice in several prospective studies on function-preserving personalized minimized gastrectomy. In the near future, the sentinel lymph node concept is expected to form the basis for establishing an ideal, personalized, minimally invasive function-preserving treatment for patients with EGC, which will improve their postoperative QOL without compromising their long-term survival. In this review article, we summarize the current status, surgical techniques, and postoperative outcomes of function-preserving gastrectomy for EGC. Full article </div> </div> <div > (This article belongs to the Special Issue Early Gastric Cancer) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessReview</div> Plant Derived Bioactive Compounds, Their Anti-Cancer Effects and In Silico Approaches as an Alternative Target Treatment Strategy for Breast Cancer: An Updated Overview <div > by <span ><div >Vijayakumar Shrihastini</div>, </span><span ><div >Pandiyan Muthuramalingam</div>, </span><span ><div >Sivakumar Adarshan</div>, </span><span ><div >Mariappan Sujitha</div>, </span><span ><div >Jen-Tsung Chen</div>, </span><span ><div >Hyunsuk Shin</div> and </span><span ><div >Manikandan Ramesh</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6222; https://doi.org/10.3390/cancers13246222 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Cancer is one of the most common malignant diseases that occur worldwide, among which breast cancer is the second leading cause of death in women. The subtypes are associated with differences in the outcome and were selected for treatments according to the estrogen [...] Read more. </div> <div > Cancer is one of the most common malignant diseases that occur worldwide, among which breast cancer is the second leading cause of death in women. The subtypes are associated with differences in the outcome and were selected for treatments according to the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor. Triple-negative breast cancer, one of the subtypes of breast cancer, is difficult to treat and can even lead to death. If breast cancer is not treated during the initial stages, it may spread to nearby organs, a process called metastasis, through the blood or lymph system. For in vitro studies, MCF-7, MDA-MB-231, MDA-MB-468, and T47B are the most commonly used breast cancer cell lines. Clinically, chemotherapy and radiotherapy are usually expensive and can also cause side effects. To overcome these issues, medicinal plants could be the best alternative for chemotherapeutic drugs with fewer side effects and cost-effectiveness. Furthermore, the genes involved in breast cancer can be regulated and synergized with signaling molecules to suppress the proliferation of breast cancer cells. In addition, nanoparticles encapsulating (nano-encapsulation) medicinal plant extracts showed a significant reduction in the apoptotic and cytotoxic activities of breast cancer cells. This present review mainly speculates an overview of the native medicinal plant derived anti-cancerous compounds with its efficiency, types and pathways involved in breast cancer along with its genes, the mechanism of breast cancer brain metastasis, chemoresistivity and its mechanism, bioinformatics approaches which could be an effective alternative for drug discovery. Full article </div> </div> <div > (This article belongs to the Special Issue Plant-Derived Targeted Strategies in Cancer) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 1692 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma <div > by <span ><div >Carolin Sauter-Meyerhoff</div>, </span><span ><div >Regina Bohnert</div>, </span><span ><div >Pascale Mazzola</div>, </span><span ><div >Viktoria Stühler</div>, </span><span ><div >Siarhei Kandabarau</div>, </span><span ><div >Florian A. Büttner</div>, </span><span ><div >Stefan Winter</div>, </span><span ><div >Lisa Herrmann</div>, </span><span ><div >Steffen Rausch</div>, </span><span ><div >Jörg Hennenlotter</div>, </span><span ><div >Falko Fend</div>, </span><span ><div >Marcus Scharpf</div>, </span><span ><div >Arnulf Stenzl</div>, </span><span ><div >Stephan Ossowski</div>, </span><span ><div >Jens Bedke</div>, </span><span ><div >Matthias Schwab</div> and </span><span ><div >Elke Schaeffeler</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6221; https://doi.org/10.3390/cancers13246221 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Metastatic renal cell carcinoma (RCC) exhibits poor prognosis. Better knowledge of distant metastases is crucial to foster personalized treatment strategies. Here, we aimed to investigate the genetic landscape of metastases, including synchronous and/or recurrent metastases to elucidate potential drug target genes and clinically [...] Read more. </div> <div > Metastatic renal cell carcinoma (RCC) exhibits poor prognosis. Better knowledge of distant metastases is crucial to foster personalized treatment strategies. Here, we aimed to investigate the genetic landscape of metastases, including synchronous and/or recurrent metastases to elucidate potential drug target genes and clinically relevant mutations in a real-world setting of patients. We assessed 81 metastases from 56 RCC patients, including synchronous and/or recurrent metastases of 19 patients. Samples were analysed through next-generation sequencing with a high coverage (~1000× mean coverage). We therefore established a novel sequencing panel comprising 32 genes with impact on RCC development. We observed a high frequency of mutations in known RCC driver genes (e.g., &gt;40% carriers of <i>VHL</i> and <i>PBRM1</i> mutations) in metastases irrespective of the metastatic site. The somatic mutational composition was significantly associated with cancer-specific survival (<i>p</i>(logrank) = 0.03). Moreover, we identified in 34 patients at least one drug target gene as well as clinically relevant mutations listed in the VICC Meta-Knowledgebase in 7%. In addition to significantly higher mutational burden in recurrent metastases compared to earlier ones, synchronous and/or recurrent metastases of individual patients, even after a time-period &gt;2 yrs, shared a high proportion of somatic events. Our data demonstrate the importance of somatic profiling in metastases for precision medicine in RCC. Full article </div> </div> <div > (This article belongs to the Special Issue Metastatic Renal Cell Carcinoma – from Diagnosis to Therapy) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 1093 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessArticle</div> Nucleolar Stress Functions Upstream to Stimulate Expression of Autophagy Regulators <div > by <span ><div >David P. P. Dannheisig</div>, </span><span ><div >Anna Schimansky</div>, </span><span ><div >Cornelia Donow</div> and </span><span ><div >Astrid S. S. Pfister</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6220; https://doi.org/10.3390/cancers13246220 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > <b> </b>Ribosome biogenesis is essential for protein synthesis, cell growth and survival. The process takes places in nucleoli and is orchestrated by various proteins, among them RNA polymerases I–III as well as ribosome biogenesis factors. Perturbation of ribosome biogenesis activates the nucleolar stress response, [...] Read more. </div> <div > <b> </b>Ribosome biogenesis is essential for protein synthesis, cell growth and survival. The process takes places in nucleoli and is orchestrated by various proteins, among them RNA polymerases I–III as well as ribosome biogenesis factors. Perturbation of ribosome biogenesis activates the nucleolar stress response, which classically triggers cell cycle arrest and apoptosis. Nucleolar stress is utilized in modern anti-cancer therapies, however, also contributes to the development of various pathologies, including cancer. Growing evidence suggests that nucleolar stress stimulates compensatory cascades, for instance bulk autophagy. However, underlying mechanisms are poorly understood. Here we demonstrate that induction of nucleolar stress activates expression of key autophagic regulators such as <i>ATG7</i> and <i>ATG16L1</i>, essential for generation of autophagosomes. We show that knockdown of the ribosomopathy factor SBDS, or of key ribosome biogenesis factors (PPAN, NPM, PES1) is associated with enhanced levels of ATG7 in cancer cells. The same holds true when interfering with RNA polymerase I function by either pharmacological inhibition (CX5461) or depletion of the transcription factor UBF1. Moreover, we demonstrate that RNA pol I inhibition by CX-5461 stimulates autophagic flux. Together, our data establish that nucleolar stress affects transcriptional regulation of autophagy. Given the contribution of both axes in propagation or cure of cancer, our data uncover a connection that might be targeted in future. Full article </div> </div> <div > (This article belongs to the Special Issue Protein Synthesis in Cancer Cells: Mechanisms and Novel Targeted Therapies) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessReview</div> Shooting at Moving and Hidden Targets—Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas <div > by <span ><div >Joanna Kałafut</div>, </span><span ><div >Arkadiusz Czerwonka</div>, </span><span ><div >Alinda Anameriç</div>, </span><span ><div >Alicja Przybyszewska-Podstawka</div>, </span><span ><div >Julia O. Misiorek</div>, </span><span ><div >Adolfo Rivero-Müller</div> and </span><span ><div >Matthias Nees</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6219; https://doi.org/10.3390/cancers13246219 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Head and Neck Squamous Cell Carcinoma (HNSCC) is often aggressive, with poor response to current therapies in approximately 40–50% of the patients. Current therapies are restricted to operation and irradiation, often combined with a small number of standard-of-care chemotherapeutic drugs, preferentially for advanced [...] Read more. </div> <div > Head and Neck Squamous Cell Carcinoma (HNSCC) is often aggressive, with poor response to current therapies in approximately 40–50% of the patients. Current therapies are restricted to operation and irradiation, often combined with a small number of standard-of-care chemotherapeutic drugs, preferentially for advanced tumour patients. Only very recently, newer targeted therapies have entered the clinics, including Cetuximab, which targets the EGF receptor (EGFR), and several immune checkpoint inhibitors targeting the immune receptor PD-1 and its ligand PD-L1. HNSCC tumour tissues are characterized by a high degree of intra-tumour heterogeneity (ITH), and non-genetic alterations that may affect both non-transformed cells, such as cancer-associated fibroblasts (CAFs), and transformed carcinoma cells. This very high degree of heterogeneity likely contributes to acquired drug resistance, tumour dormancy, relapse, and distant or lymph node metastasis. ITH, in turn, is likely promoted by pronounced tumour cell plasticity, which manifests in highly dynamic and reversible phenomena such as of partial or hybrid forms of epithelial-to-mesenchymal transition (EMT), and enhanced tumour stemness. Stemness and tumour cell plasticity are strongly promoted by Notch signalling, which remains poorly understood especially in HNSCC. Here, we aim to elucidate how Notch signal may act both as a tumour suppressor and proto-oncogenic, probably during different stages of tumour cell initiation and progression. Notch signalling also interacts with numerous other signalling pathways, that may also have a decisive impact on tumour cell plasticity, acquired radio/chemoresistance, and metastatic progression of HNSCC. We outline the current stage of research related to Notch signalling, and how this pathway may be intricately interconnected with other, druggable targets and signalling mechanisms in HNSCC. Full article </div> </div> <div > (This article belongs to the Special Issue Molecular Targets for Head and Neck Cancer) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessReview</div> Molecular Classification and Therapeutic Targets in Ependymoma <div > by <span ><div >Thomas Larrew</div>, </span><span ><div >Brian Fabian Saway</div>, </span><span ><div >Stephen R. Lowe</div> and </span><span ><div >Adriana Olar</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6218; https://doi.org/10.3390/cancers13246218 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Ependymoma is a biologically diverse tumor wherein molecular classification has superseded traditional histological grading based on its superior ability to characterize behavior, prognosis, and possible targeted therapies. The current, updated molecular classification of ependymoma consists of ten distinct subgroups spread evenly among the [...] Read more. </div> <div > Ependymoma is a biologically diverse tumor wherein molecular classification has superseded traditional histological grading based on its superior ability to characterize behavior, prognosis, and possible targeted therapies. The current, updated molecular classification of ependymoma consists of ten distinct subgroups spread evenly among the spinal, infratentorial, and supratentorial compartments, each with its own distinct clinical and molecular characteristics. In this review, the history, histopathology, standard of care, prognosis, oncogenic drivers, and hypothesized molecular targets for all subgroups of ependymoma are explored. This review emphasizes that despite the varied behavior of the ependymoma subgroups, it remains clear that research must be performed to further elucidate molecular targets for these tumors. Although not all ependymoma subgroups are oncologically aggressive, development of targeted therapies is essential, particularly for cases where surgical resection is not an option without causing significant morbidity. The development of molecular therapies must rely on building upon our current understanding of ependymoma oncogenesis, as well as cultivating transfer of knowledge based on malignancies with similar genomic alterations. Full article </div> </div> <div > (This article belongs to the Special Issue Updates on Molecular Targeted Therapies for CNS Tumors) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessReview</div> Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy <div > by <span ><div >Valentina Aleotti</div>, </span><span ><div >Cristina Catoni</div>, </span><span ><div >Cristina Poggiana</div>, </span><span ><div >Antonio Rosato</div>, </span><span ><div >Antonella Facchinetti</div> and </span><span ><div >Maria Chiara Scaini</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6217; https://doi.org/10.3390/cancers13246217 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Malignant melanoma is the most serious, life-threatening form of all dermatologic diseases, with a poor prognosis in the presence of metastases and advanced disease. Despite recent advances in targeted therapy and immunotherapy, there is still a critical need for a better understanding of [...] Read more. </div> <div > Malignant melanoma is the most serious, life-threatening form of all dermatologic diseases, with a poor prognosis in the presence of metastases and advanced disease. Despite recent advances in targeted therapy and immunotherapy, there is still a critical need for a better understanding of the fundamental mechanisms behind melanoma progression and resistance onset. Recent advances in genome-wide methylation methods have revealed that aberrant changes in the pattern of DNA methylation play an important role in many aspects of cancer progression, including cell proliferation and migration, evasion of cell death, invasion, and metastasization. The purpose of the current review was to gather evidence regarding the usefulness of DNA methylation tracking in liquid biopsy as a potential biomarker in melanoma. We investigated the key genes and signal transduction pathways that have been found to be altered epigenetically in melanoma. We then highlighted the circulating tumor components present in blood, including circulating melanoma cells (CMC), circulating tumor DNA (ctDNA), and tumor-derived extracellular vesicles (EVs), as a valuable source for identifying relevant aberrations in DNA methylation. Finally, we focused on DNA methylation signatures as a marker for tracking response to therapy and resistance, thus facilitating personalized medicine and decision-making in the treatment of melanoma patients. Full article </div> </div> <div > (This article belongs to the Special Issue DNA Methylation Markers in Liquid Biopsies) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 36 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer <div > by <span ><div >Koldo Garcia-Etxebarria</div>, </span><span ><div >Marc Clos-Garcia</div>, </span><span ><div >Oiana Telleria</div>, </span><span ><div >Beatriz Nafría</div>, </span><span ><div >Cristina Alonso</div>, </span><span ><div >Marta Iruarrizaga-Lejarreta</div>, </span><span ><div >Andre Franke</div>, </span><span ><div >Anais Crespo</div>, </span><span ><div >Agueda Iglesias</div>, </span><span ><div >Joaquín Cubiella</div>, </span><span ><div >Luis Bujanda</div> and </span><span ><div >Juan Manuel Falcón-Pérez</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6216; https://doi.org/10.3390/cancers13246216 - 10 Dec 2021 </div> <div > Abstract <div > Background: Colorectal cancer (CRC), a major health concern, is developed depending on environmental, genetic and microbial factors. The microbiome and metabolome have been analyzed to study their role in CRC. However, the interplay of host genetics with those layers in CRC remains unclear. [...] Read more. </div> <div > Background: Colorectal cancer (CRC), a major health concern, is developed depending on environmental, genetic and microbial factors. The microbiome and metabolome have been analyzed to study their role in CRC. However, the interplay of host genetics with those layers in CRC remains unclear. Methods: 120 individuals were sequenced and association analyses were carried out for adenoma and CRC risk, and for selected components of the microbiome and metabolome. The epistasis between genes located in cholesterol pathways was analyzed; modifiable risk factors were studied using Mendelian randomization; and the three omic layers were used to integrate their data and to build risk prediction models. Results: We detected genetic variants that were associated to components of metabolome or microbiome and adenoma or CRC risk (e.g., in <i>LINC01605</i>, <i>PROKR2</i> and <i>CCSER1</i> genes). In addition, we found interactions between genes of cholesterol metabolism, and HDL cholesterol levels affected adenoma (<i>p</i> = 0.0448) and CRC (<i>p</i> = 0.0148) risk. The combination of the three omic layers to build risk prediction models reached high AUC values (&gt;0.91). Conclusions: The use of the three omic layers allowed for the finding of biological mechanisms related to the development of adenoma and CRC, and each layer provided complementary information to build risk prediction models. Full article </div> </div> <div > (This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 3070 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells <div > by <span ><div >David King</div>, </span><span ><div >Harriet E. D. Southgate</div>, </span><span ><div >Saskia Roetschke</div>, </span><span ><div >Polly Gravells</div>, </span><span ><div >Leona Fields</div>, </span><span ><div >Jessica B. Watson</div>, </span><span ><div >Lindi Chen</div>, </span><span ><div >Devon Chapman</div>, </span><span ><div >Daniel Harrison</div>, </span><span ><div >Daniel Yeomanson</div>, </span><span ><div >Nicola J. Curtin</div>, </span><span ><div >Deborah A. Tweddle</div> and </span><span ><div >Helen E. Bryant</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6215; https://doi.org/10.3390/cancers13246215 - 10 Dec 2021 </div> <div > Abstract <div > Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in pre-clinical models of high-risk NB. Amplification of the oncogene [...] Read more. </div> <div > Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in pre-clinical models of high-risk NB. Amplification of the oncogene <i>MYCN</i> always imparts high-risk disease and occurs in 25% of all NB. Here, we show that MYCN-induced replication stress directly increases sensitivity to the ATR inhibitors VE-821 and AZD6738. PARP inhibition with Olaparib also results in replication stress and ATR activation, and sensitises NB cells to ATR inhibition independently of <i>MYCN</i> status, with synergistic levels of cell death seen in MYCN expressing ATR- and PARP-inhibited cells. Mechanistically, we demonstrate that ATR inhibition increases the number of persistent stalled and collapsed replication forks, exacerbating replication stress. It also abrogates S and G2 cell cycle checkpoints leading to death during mitosis in cells treated with an ATR inhibitor combined with PARP inhibition. In summary, increased replication stress through high MYCN expression, PARP inhibition or chemotherapeutic agents results in sensitivity to ATR inhibition. Our findings provide a mechanistic rationale for the inclusion of ATR and PARP inhibitors as a potential treatment strategy for high-risk NB. Full article </div> </div> <div > (This article belongs to the Special Issue Targeted Therapies for Pediatric Solid Tumors) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessFeature PaperReview</div> The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective <div > by <span ><div >Yi Xiao</div> and </span><span ><div >Jixin Dong</div></span> </div> <div > Cancers <b>2021</b>, 13(24), 6214; https://doi.org/10.3390/cancers13246214 - 10 Dec 2021 </div> <div > Abstract <div > Cell cycle progression is an elaborate process that requires stringent control for normal cellular function. Defects in cell cycle control, however, contribute to genomic instability and have become a characteristic phenomenon in cancers. Over the years, advancement in the understanding of disrupted cell [...] Read more. </div> <div > Cell cycle progression is an elaborate process that requires stringent control for normal cellular function. Defects in cell cycle control, however, contribute to genomic instability and have become a characteristic phenomenon in cancers. Over the years, advancement in the understanding of disrupted cell cycle regulation in tumors has led to the development of powerful anti-cancer drugs. Therefore, an in-depth exploration of cell cycle dysregulation in cancers could provide therapeutic avenues for cancer treatment. The Hippo pathway is an evolutionarily conserved regulator network that controls organ size, and its dysregulation is implicated in various types of cancers. Although the role of the Hippo pathway in oncogenesis has been widely investigated, its role in cell cycle regulation has not been comprehensively scrutinized. Here, we specifically focus on delineating the involvement of the Hippo pathway in cell cycle regulation. To that end, we first compare the structural as well as functional conservation of the core Hippo pathway in yeasts, flies, and mammals. Then, we detail the multi-faceted aspects in which the core components of the mammalian Hippo pathway and their regulators affect the cell cycle, particularly with regard to the regulation of E2F activity, the G1 tetraploidy checkpoint, DNA synthesis, DNA damage checkpoint, centrosome dynamics, and mitosis. Finally, we briefly discuss how a collective understanding of cell cycle regulation and the Hippo pathway could be weaponized in combating cancer. Full article </div> </div> <div > (This article belongs to the Special Issue Hippo Signaling Pathway in Cancers) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> </div> <div > More Articles... </div> </div> </div> </div> <div > <div > <div > <div > <a > Submit to <i>Cancers</i> </a> Review for Cancers <div > Share </div> </div> <div > <h2 >Journal Menu</h2> ► ▼ Journal Menu <ul > <li > <ul> <li > Cancers Home </li> <li > Aims Scope </li> <li > Editorial Board </li> <li > Reviewer Board </li> <li > Topical Advisory Panel </li> <li > Instructions for Authors </li> <li > Special Issues </li> <li > Sections Collections </li> <li > Article Processing Charge </li> <li > Indexing Archiving </li> <li > Editor's Choice Articles </li> <li > Most Cited Viewed </li> <li > Journal Statistics </li> <li > Journal History </li> <li > Journal Awards </li> <li > Society Collaborations </li> <li > Conferences </li> <li > Editorial Office </li> </ul> </li> </ul> </div> <h2 >Journal Browser</h2> ► ▼ Journal Browser <div > <div > <ul > <li > <a > <i > arrow_forward_ios </i> Forthcoming issue </a> <a > <i > arrow_forward_ios </i> Current issue </a> </li> <div > <div > <div > <li > Vol. 13 (2021) </li> <li > Vol. 12 (2020) </li> <li > Vol. 11 (2019) </li> <li > Vol. 10 (2018) </li> <li > Vol. 9 (2017) </li> <li > Vol. 8 (2016) </li> <li > Vol. 7 (2015) </li> <li > Vol. 6 (2014) </li> <li > Vol. 5 (2013) </li> <li > Vol. 4 (2012) </li> <li > Vol. 3 (2011) </li> <li > Vol. 2 (2010) </li> <li > Vol. 1 (2009) </li> </div> </div> </div> </ul> </div> </div> </div> </div> <div > <div > <h2>Highly Accessed Articles</h2> </div> <div > <div > View More... </div> </div> </div> <div > <div > <h2>Latest Books</h2> </div> <div > <div > More Open Access Books... </div> </div> </div> </div> <div > <div > <div > <h2>E-Mail Alert</h2> </div> </div> <div > <div > <h2>News</h2> </div> <div > <div > 22 November 2021 720 MDPI Editorial Board Members Receiving "2021 Highly Cited Researchers" Distinction </div> <div > 16 November 2021 Topical Advisory Panel Established to Support Editorial Board </div> <div > 25 October 2021 Open Access Week 2021 | It Matters How We Open Knowledge: Building Structural Equity, 25–31 October </div> <div > More News Announcements... </div> </div> </div> <div > <div > <h2>Topics</h2> </div> <div > <div ><div> Topic in Biomedicines, Pharmaceutics, Pharmaceuticals, Cancers, Vaccines</div> Animal Model in Biomedical Research Editor-in-Chief: Marc EkkerDeadline: 31 December 2021</div> <div ><div> Topic in Biology, Cancers</div> Application of Big Medical Data in Precision Medicine Editors-in-Chief: Yi Zhao, Jinpu Yu, Haifeng Zhang, Min Hu, Jincheng GuoDeadline: 31 March 2022</div> <div ><div> Topic in Biomolecules, Cancers, Cells, Current Oncology</div> Advances in Ovarian Cancer Research: From Biology to Therapeutics Editor-in-Chief: Christina M. AnnunziataDeadline: 31 May 2022</div> <div ><div> Topic in Biomolecules, Cancers, Cells, Current Oncology, Onco</div> Adaptation Mechanisms in Therapy-Resistant Breast Cancer Deadline: 31 July 2022</div> <div > More Topics </div> </div> </div> <div > <div > <h2>Conferences</h2> </div> <div > <div > Announce Your Conference </div> <div > 14–16 February 2022 IECC 2022: Tumor Microenvironment Heterogeneity in Cancer Progression: Challenge or Opportunity</div> <div > More Conferences... </div> </div> </div> <div > <div > <h2>Special Issues</h2> </div> <div > <div > Edit a Special Issue </div> <div ><div> Special Issue in Cancers</div> Nuclear Receptors and Cancer Guest Editors: Zeynep Madak-Erdogan, Matthew SikoraDeadline: 15 December 2021</div> <div ><div> Special Issue in Cancers</div> Perioperative Interventions and Oncological Outcome in Surgical Cancer Patients Guest Editor: Donal J BuggyDeadline: 31 December 2021</div> <div ><div> Special Issue in Cancers</div> Gammopathies of Certain Significance: Managing MGUS and Smoldering Myeloma Guest Editors: Maximilian Merz, Hartmut GoldschmidtDeadline: 1 January 2022</div> <div ><div> Special Issue in Cancers</div> Nanoparticle-Based Combination Therapy and Diagnosis for Cancer Guest Editors: Elena Reddi, Francesca MoretDeadline: 15 January 2022</div> <div > More Special Issues </div> </div> </div> <div > <div > <h2>Topical Collections</h2> </div> <div > <div ><div> Topical Collection in Cancers</div> Urological Cancer Collection Editor: José I. López</div> <div ><div> Topical Collection in Cancers</div> Drug Resistance and Novel Therapies in Cancers Collection Editor: Zhixiang Wang</div> <div ><div> Topical Collection in Cancers</div> The Role of Non-coding RNA in Cancer Collection Editor: Lyndsay Rhodes</div> <div ><div> Topical Collection in Cancers</div> Deciphering the Crosstalk between Tumor Cells and Their Microenvironment: From Molecular Aspects to Therapeutic Implications Collection Editors: Patrizia Limonta, Fabrizio Fontana</div> <div > More Topical Collections </div> </div> </div> <div > <div > <h2>Jobs in Research</h2> </div> <div > <div > Post New Job Opening </div> </div> </div> </div> </div> </div> </section> <div > <div > Cancers, EISSN 2072-6694, Published by MDPI <span> Disclaimer <div > The statements, opinions and data contained in the journal Cancers are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. </div> </span> <div > RSS Content Alert </div> </div> <div > <div > <h3> Further Information </h3> <a > Article Processing Charges </a> <a > Pay an Invoice </a> <a > Open Access Policy </a> <a > Contact MDPI </a> <a > Jobs at MDPI </a> </div> <div > <h3> Guidelines </h3> <a > For Authors </a> <a > For Reviewers </a> <a > For Editors </a> <a > For Librarians </a> <a > For Publishers </a> <a > For Societies </a> </div> <div > <h3> MDPI Initiatives </h3> <a > Sciforum </a> <a > MDPI Books </a> <a > Preprints </a> <a > Scilit </a> <a > SciProfiles </a> <a > Encyclopedia </a> <a > JAMS </a> <a > Proceedings Series </a> </div> <div > <h3> Follow MDPI </h3> <a > LinkedIn </a> <a > Facebook </a> <a > Twitter </a> </div> </div> <div > <div > <div > © 1996-2021 MDPI (Basel, Switzerland) unless otherwise stated </div> <div > <a > Disclaimer </a> <div > The statements, opinions and data contained in the journals are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. </div> <a > Terms and Conditions </a> <a > Privacy Policy </a> </div> </div> </div> </div> <div > <div > We use cookies on our website to ensure you get the best experience. Read more about our cookies <a >here</a>. </div> <div > <a >Accept</a> </div> </div> <div > <div > We have just recently launched a new version of our website. Help us to further improve by taking part in this short 5 minute survey here. here. </div> <div > <a >Never show this again</a> </div> </div> </div> <div > <div > <div > <h2 >Share Link</h2> </div> <div > <a >Copy</a> </div> </div> <a > <i >clear</i> </a> </div> <div > <div > <div > <h2 >Share</h2> </div> </div> <a > <i >clear</i> </a> </div> <a >Back to TopTop</a> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, tag: body, level: 1" node_number="1"> <div class="valid" valid="valid" title="valid: True, node: 2, tag: div, level: 2" node_number="2"> <div class="valid" valid="valid" title="valid: True, node: 3, tag: div, level: 3" node_number="3"> <div class="valid" valid="valid" title="valid: True, node: 4, tag: div, level: 4" node_number="4"> <a class="valid" valid="valid" title="valid: True, node: 5, tag: a, level: 5" node_number="5"> <h2 class="valid" valid="valid" title="valid: True, node: 6, tag: h2, level: 6" node_number="6">25th Anniversary</h2> </a> <a class="valid" valid="valid" title="valid: True, node: 7, tag: a, level: 5" node_number="7"> <h2 class="valid" valid="valid" title="valid: True, node: 8, tag: h2, level: 6" node_number="8">Journals</h2> </a> <div class="valid" valid="valid" title="valid: True, node: 9, tag: div, level: 5" node_number="9"> <div class="valid" valid="valid" title="valid: True, node: 10, tag: div, level: 6" node_number="10"> <h2 class="valid" valid="valid" title="valid: True, node: 11, tag: h2, level: 7" node_number="11">Information</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 12, tag: div, level: 6" node_number="12"> <div class="valid" valid="valid" title="valid: True, node: 13, tag: div, level: 7" node_number="13"> <div class="valid" valid="valid" title="valid: True, node: 14, tag: div, level: 8" node_number="14"> <a class="valid" valid="valid" title="valid: True, node: 15, tag: a, level: 9" node_number="15">For Authors</a> <a class="valid" valid="valid" title="valid: True, node: 16, tag: a, level: 9" node_number="16">For Reviewers</a> <a class="valid" valid="valid" title="valid: True, node: 17, tag: a, level: 9" node_number="17">For Editors</a> <a class="valid" valid="valid" title="valid: True, node: 18, tag: a, level: 9" node_number="18">For Librarians</a> <a class="valid" valid="valid" title="valid: True, node: 19, tag: a, level: 9" node_number="19">For Publishers</a> <a class="valid" valid="valid" title="valid: True, node: 20, tag: a, level: 9" node_number="20">For Societies</a> </div> <div class="valid" valid="valid" title="valid: True, node: 21, tag: div, level: 8" node_number="21"> <a class="valid" valid="valid" title="valid: True, node: 22, tag: a, level: 9" node_number="22">Article Processing Charges</a> <a class="valid" valid="valid" title="valid: True, node: 23, tag: a, level: 9" node_number="23">Open Access Policy</a> <a class="valid" valid="valid" title="valid: True, node: 24, tag: a, level: 9" node_number="24">Institutional Open Access Program</a> <a class="valid" valid="valid" title="valid: True, node: 25, tag: a, level: 9" node_number="25">Editorial Process</a> <a class="valid" valid="valid" title="valid: True, node: 26, tag: a, level: 9" node_number="26">Awards</a> <a class="valid" valid="valid" title="valid: True, node: 27, tag: a, level: 9" node_number="27">Research and Publication Ethics</a> </div> </div> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 28, tag: a, level: 5" node_number="28"> <h2 class="valid" valid="valid" title="valid: True, node: 29, tag: h2, level: 6" node_number="29">Author Services</h2> </a> <div class="valid" valid="valid" title="valid: True, node: 30, tag: div, level: 5" node_number="30"> <div class="valid" valid="valid" title="valid: True, node: 31, tag: div, level: 6" node_number="31"> <h2 class="valid" valid="valid" title="valid: True, node: 32, tag: h2, level: 7" node_number="32">Initiatives</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 33, tag: div, level: 6" node_number="33"> <div class="valid" valid="valid" title="valid: True, node: 34, tag: div, level: 7" node_number="34"> <div class="valid" valid="valid" title="valid: True, node: 35, tag: div, level: 8" node_number="35"> <a class="valid" valid="valid" title="valid: True, node: 36, tag: a, level: 9" node_number="36">Sciforum</a> <a class="valid" valid="valid" title="valid: True, node: 37, tag: a, level: 9" node_number="37">MDPI Books</a> <a class="valid" valid="valid" title="valid: True, node: 38, tag: a, level: 9" node_number="38">Preprints</a> <a class="valid" valid="valid" title="valid: True, node: 39, tag: a, level: 9" node_number="39">Scilit</a> <a class="valid" valid="valid" title="valid: True, node: 40, tag: a, level: 9" node_number="40">SciProfiles</a> <a class="valid" valid="valid" title="valid: True, node: 41, tag: a, level: 9" node_number="41">Encyclopedia</a> <a class="valid" valid="valid" title="valid: True, node: 42, tag: a, level: 9" node_number="42">JAMS</a> <a class="valid" valid="valid" title="valid: True, node: 43, tag: a, level: 9" node_number="43">Proceedings Series</a> </div> </div> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 44, tag: a, level: 5" node_number="44"> <h2 class="valid" valid="valid" title="valid: True, node: 45, tag: h2, level: 6" node_number="45">About</h2> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 46, tag: div, level: 4" node_number="46"> <a class="valid" valid="valid" title="valid: True, node: 47, tag: a, level: 5" node_number="47">Sign In / Sign Up</a> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 48, tag: div, level: 2" node_number="48"> <h2 class="valid" valid="valid" title="valid: True, node: 49, tag: h2, level: 3" node_number="49">Notice</h2> <a class="valid" valid="valid" title="valid: True, node: 50, tag: a, level: 3" node_number="50"> <i class="valid" valid="valid" title="valid: True, node: 51, tag: i, level: 4" node_number="51">clear</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 52, tag: div, level: 2" node_number="52"> <div class="valid" valid="valid" title="valid: True, node: 53, tag: div, level: 3" node_number="53"> <div class="valid" valid="valid" title="valid: True, node: 54, tag: div, level: 4" node_number="54"> <h2 class="valid" valid="valid" title="valid: True, node: 55, tag: h2, level: 5" node_number="55">Notice</h2> <p class="valid" valid="valid" title="valid: True, node: 56, tag: p, level: 5" node_number="56"> You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader. </p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 57, tag: div, level: 3" node_number="57"> <div class="valid" valid="valid" title="valid: True, node: 58, tag: div, level: 4" node_number="58"> <a class="valid" valid="valid" title="valid: True, node: 59, tag: a, level: 5" node_number="59">Continue</a> <a class="valid" valid="valid" title="valid: True, node: 60, tag: a, level: 5" node_number="60">Cancel</a> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 61, tag: a, level: 3" node_number="61"> <i class="valid" valid="valid" title="valid: True, node: 62, tag: i, level: 4" node_number="62">clear</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 63, tag: div, level: 2" node_number="63"> <p class="valid" valid="valid" title="valid: True, node: 64, tag: p, level: 3" node_number="64"> All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 65, tag: div, level: 2" node_number="65"> <p class="valid" valid="valid" title="valid: True, node: 66, tag: p, level: 3" node_number="66"> Feature Papers represent the most advanced research with significant potential for high impact in the field. Feature Papers are submitted upon individual invitation or recommendation by the scientific editors and undergo peer review prior to publication. </p> <p class="valid" valid="valid" title="valid: True, node: 67, tag: p, level: 3" node_number="67"> The Feature Paper can be either an original research article, a substantial novel research study that often involves several techniques or approaches, or a comprehensive review paper with concise and precise updates on the latest progress in the field that systematically reviews the most exciting advances in scientific literature. This type of paper provides an outlook on future directions of research or possible applications. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 68, tag: div, level: 2" node_number="68"> <p class="valid" valid="valid" title="valid: True, node: 69, tag: p, level: 3" node_number="69"> Editor&#8217;s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to authors, or important in this field. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 70, tag: div, level: 2" node_number="70"> <div class="valid" valid="valid" title="valid: True, node: 71, tag: div, level: 3" node_number="71">  </div> <section class="valid" valid="valid" title="valid: True, node: 72, tag: section, level: 3" node_number="72"> <header class="valid" valid="valid" title="valid: True, node: 73, tag: header, level: 4" node_number="73"> <div class="valid" valid="valid" title="valid: True, node: 74, tag: div, level: 5" node_number="74"> <div class="valid" valid="valid" title="valid: True, node: 75, tag: div, level: 6" node_number="75"> <div class="valid" valid="valid" title="valid: True, node: 76, tag: div, level: 7" node_number="76"> <ul class="valid" valid="valid" title="valid: True, node: 77, tag: ul, level: 8" node_number="77"> <li class="valid" valid="valid" title="valid: True, node: 78, tag: li, level: 9" node_number="78"> <a class="valid" valid="valid" title="valid: True, node: 79, tag: a, level: 10" node_number="79">25th Anniversary</a> </li> <li class="valid" valid="valid" title="valid: True, node: 80, tag: li, level: 9" node_number="80"> <a class="valid" valid="valid" title="valid: True, node: 81, tag: a, level: 10" node_number="81">Journals</a> </li> <li class="valid" valid="valid" title="valid: True, node: 82, tag: li, level: 9" node_number="82"> <a class="valid" valid="valid" title="valid: True, node: 83, tag: a, level: 10" node_number="83">Information</a> <ul class="valid" valid="valid" title="valid: True, node: 84, tag: ul, level: 10" node_number="84"> <li class="valid" valid="valid" title="valid: True, node: 85, tag: li, level: 11" node_number="85"> <div class="valid" valid="valid" title="valid: True, node: 86, tag: div, level: 12" node_number="86"> <div class="valid" valid="valid" title="valid: True, node: 87, tag: div, level: 13" node_number="87"> <ul class="valid" valid="valid" title="valid: True, node: 88, tag: ul, level: 14" node_number="88"> <li title="valid: False, node: 89, tag: li, level: 15" node_number="89"> <a title="valid: False, node: 90, tag: a, level: 16" node_number="90">For Authors</a> </li> <li title="valid: False, node: 91, tag: li, level: 15" node_number="91"> <a title="valid: False, node: 92, tag: a, level: 16" node_number="92">For Reviewers</a> </li> <li title="valid: False, node: 93, tag: li, level: 15" node_number="93"> <a title="valid: False, node: 94, tag: a, level: 16" node_number="94">For Editors</a> </li> <li title="valid: False, node: 95, tag: li, level: 15" node_number="95"> <a title="valid: False, node: 96, tag: a, level: 16" node_number="96">For Librarians</a> </li> <li title="valid: False, node: 97, tag: li, level: 15" node_number="97"> <a title="valid: False, node: 98, tag: a, level: 16" node_number="98">For Publishers</a> </li> <li title="valid: False, node: 99, tag: li, level: 15" node_number="99"> <a title="valid: False, node: 100, tag: a, level: 16" node_number="100">For Societies</a> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 101, tag: div, level: 13" node_number="101"> <ul class="valid" valid="valid" title="valid: True, node: 102, tag: ul, level: 14" node_number="102"> <li title="valid: False, node: 103, tag: li, level: 15" node_number="103"> <a title="valid: False, node: 104, tag: a, level: 16" node_number="104">Article Processing Charges</a> </li> <li title="valid: False, node: 105, tag: li, level: 15" node_number="105"> <a title="valid: False, node: 106, tag: a, level: 16" node_number="106">Open Access Policy</a> </li> <li title="valid: False, node: 107, tag: li, level: 15" node_number="107"> <a title="valid: False, node: 108, tag: a, level: 16" node_number="108">Institutional Open Access Program</a> </li> <li title="valid: False, node: 109, tag: li, level: 15" node_number="109"> <a title="valid: False, node: 110, tag: a, level: 16" node_number="110">Editorial Process</a> </li> <li title="valid: False, node: 111, tag: li, level: 15" node_number="111"> <a title="valid: False, node: 112, tag: a, level: 16" node_number="112">Awards</a> </li> <li title="valid: False, node: 113, tag: li, level: 15" node_number="113"> <a title="valid: False, node: 114, tag: a, level: 16" node_number="114">Research and Publication Ethics</a> </li> </ul> </div> </div> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 115, tag: li, level: 9" node_number="115"> <a class="valid" valid="valid" title="valid: True, node: 116, tag: a, level: 10" node_number="116">Author Services</a> </li> <li class="valid" valid="valid" title="valid: True, node: 117, tag: li, level: 9" node_number="117"> <a class="valid" valid="valid" title="valid: True, node: 118, tag: a, level: 10" node_number="118">Initiatives</a> <ul class="valid" valid="valid" title="valid: True, node: 119, tag: ul, level: 10" node_number="119"> <li class="valid" valid="valid" title="valid: True, node: 120, tag: li, level: 11" node_number="120"> <div class="valid" valid="valid" title="valid: True, node: 121, tag: div, level: 12" node_number="121"> <div class="valid" valid="valid" title="valid: True, node: 122, tag: div, level: 13" node_number="122"> <ul class="valid" valid="valid" title="valid: True, node: 123, tag: ul, level: 14" node_number="123"> <li title="valid: False, node: 124, tag: li, level: 15" node_number="124"> <a title="valid: False, node: 125, tag: a, level: 16" node_number="125"> Sciforum </a> </li> <li title="valid: False, node: 126, tag: li, level: 15" node_number="126"> <a title="valid: False, node: 127, tag: a, level: 16" node_number="127"> MDPI Books </a> </li> <li title="valid: False, node: 128, tag: li, level: 15" node_number="128"> <a title="valid: False, node: 129, tag: a, level: 16" node_number="129"> Preprints </a> </li> <li title="valid: False, node: 130, tag: li, level: 15" node_number="130"> <a title="valid: False, node: 131, tag: a, level: 16" node_number="131"> Scilit </a> </li> <li title="valid: False, node: 132, tag: li, level: 15" node_number="132"> <a title="valid: False, node: 133, tag: a, level: 16" node_number="133"> SciProfiles </a> </li> <li title="valid: False, node: 134, tag: li, level: 15" node_number="134"> <a title="valid: False, node: 135, tag: a, level: 16" node_number="135"> Encyclopedia </a> </li> <li title="valid: False, node: 136, tag: li, level: 15" node_number="136"> <a title="valid: False, node: 137, tag: a, level: 16" node_number="137"> JAMS </a> </li> <li title="valid: False, node: 138, tag: li, level: 15" node_number="138"> <a title="valid: False, node: 139, tag: a, level: 16" node_number="139"> Proceedings Series </a> </li> </ul> </div> </div> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 140, tag: li, level: 9" node_number="140"> <a class="valid" valid="valid" title="valid: True, node: 141, tag: a, level: 10" node_number="141">About</a> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 142, tag: div, level: 7" node_number="142"> <div class="valid" valid="valid" title="valid: True, node: 143, tag: div, level: 8" node_number="143"> <a class="valid" valid="valid" title="valid: True, node: 144, tag: a, level: 9" node_number="144">Sign In / Sign Up</a> <a class="valid" valid="valid" title="valid: True, node: 145, tag: a, level: 9" node_number="145">Submit</a> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 146, tag: div, level: 5" node_number="146"> <div class="valid" valid="valid" title="valid: True, node: 147, tag: div, level: 6" node_number="147"> <div class="valid" valid="valid" title="valid: True, node: 148, tag: div, level: 7" node_number="148"> <div class="valid" valid="valid" title="valid: True, node: 149, tag: div, level: 8" node_number="149"> <a class="valid" valid="valid" title="valid: True, node: 150, tag: a, level: 9" node_number="150"> Covered in: PubMed </a> </div></div> <div class="valid" valid="valid" title="valid: True, node: 151, tag: div, level: 7" node_number="151"> <div class="valid" valid="valid" title="valid: True, node: 152, tag: div, level: 8" node_number="152"> <a class="valid" valid="valid" title="valid: True, node: 153, tag: a, level: 9" node_number="153"> IMPACTFACTOR 6.639 </a> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 154, tag: div, level: 6" node_number="154"> Journals </div> <div class="valid" valid="valid" title="valid: True, node: 155, tag: div, level: 6" node_number="155"> Cancers </div> </div> </header> <div class="valid" valid="valid" title="valid: True, node: 156, tag: div, level: 4" node_number="156"> <div class="valid" valid="valid" title="valid: True, node: 157, tag: div, level: 5" node_number="157"> <div class="valid" valid="valid" title="valid: True, node: 158, tag: div, level: 6" node_number="158"> <div class="valid" valid="valid" title="valid: True, node: 159, tag: div, level: 7" node_number="159"> <div class="valid" valid="valid" title="valid: True, node: 160, tag: div, level: 8" node_number="160"> <ul class="valid" valid="valid" title="valid: True, node: 161, tag: ul, level: 9" node_number="161"> <li class="valid" valid="valid" title="valid: True, node: 162, tag: li, level: 10" node_number="162"> <a class="valid" valid="valid" title="valid: True, node: 163, tag: a, level: 11" node_number="163"> <div class="valid" valid="valid" title="valid: True, node: 164, tag: div, level: 12" node_number="164"> &#8216;Palliative-D&#8217;&#8212;A Randomized Controlled Trial on the Effects of Vitamin D in Palliative Cancer Care </div> </a> </li> <li class="valid" valid="valid" title="valid: True, node: 165, tag: li, level: 10" node_number="165"> <a class="valid" valid="valid" title="valid: True, node: 166, tag: a, level: 11" node_number="166"> <div class="valid" valid="valid" title="valid: True, node: 167, tag: div, level: 12" node_number="167"> Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs </div> </a> </li> <li class="valid" valid="valid" title="valid: True, node: 168, tag: li, level: 10" node_number="168"> <a class="valid" valid="valid" title="valid: True, node: 169, tag: a, level: 11" node_number="169"> <div class="valid" valid="valid" title="valid: True, node: 170, tag: div, level: 12" node_number="170"> Epigenetic Immunomodulators to Enhance Immunotherapy </div> </a> </li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 171, tag: div, level: 7" node_number="171"> <div class="valid" valid="valid" title="valid: True, node: 172, tag: div, level: 8" node_number="172"> <h2 class="valid" valid="valid" title="valid: True, node: 173, tag: h2, level: 9" node_number="173">Journal Description</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 174, tag: div, level: 8" node_number="174"> <div class="valid" valid="valid" title="valid: True, node: 175, tag: div, level: 9" node_number="175"> <h1 class="valid" valid="valid" title="valid: True, node: 176, tag: h1, level: 10" node_number="176"> Cancers </h1> <div class="valid" valid="valid" title="valid: True, node: 177, tag: div, level: 10" node_number="177"> Cancers is a <a class="valid" valid="valid" title="valid: True, node: 178, tag: a, level: 11" node_number="178">peer-reviewed</a>, open access journal of oncology published semimonthly online by MDPI. The <a class="valid" valid="valid" title="valid: True, node: 179, tag: a, level: 11" node_number="179">Irish Association for Cancer Research (IACR)</a>, <a class="valid" valid="valid" title="valid: True, node: 180, tag: a, level: 11" node_number="180">Signal Transduction Society (STS)</a> and&#160;<a class="valid" valid="valid" title="valid: True, node: 181, tag: a, level: 11" node_number="181">Spanish Association for Cancer Research (ASEICA)</a> are affiliated with Cancers and their members receive a discount on the article processing charges. <ul class="valid" valid="valid" title="valid: True, node: 182, tag: ul, level: 11" node_number="182"> <li class="valid" valid="valid" title="valid: True, node: 183, tag: li, level: 12" node_number="183">Open Access&#8212; free for readers, with <a class="valid" valid="valid" title="valid: True, node: 184, tag: a, level: 13" node_number="184">article processing charges (APC)</a> paid by authors or their institutions.</li> <li class="valid" valid="valid" title="valid: True, node: 185, tag: li, level: 12" node_number="185">High Visibility: indexed&#160;within <a class="valid" valid="valid" title="valid: True, node: 186, tag: a, level: 13" node_number="186">Scopus</a>, <a class="valid" valid="valid" title="valid: True, node: 187, tag: a, level: 13" node_number="187">SCIE (Web of Science)</a>, <a class="valid" valid="valid" title="valid: True, node: 188, tag: a, level: 13" node_number="188">PubMed</a>, <a class="valid" valid="valid" title="valid: True, node: 189, tag: a, level: 13" node_number="189">PMC</a>, <a class="valid" valid="valid" title="valid: True, node: 190, tag: a, level: 13" node_number="190">Embase</a>, <a class="valid" valid="valid" title="valid: True, node: 191, tag: a, level: 13" node_number="191">CAPlus / SciFinder</a>, and many&#160;<a class="valid" valid="valid" title="valid: True, node: 192, tag: a, level: 13" node_number="192">other databases</a>.</li> <li class="valid" valid="valid" title="valid: True, node: 193, tag: li, level: 12" node_number="193">Journal Rank:&#160;JCR&#160;- Q1 (Oncology) / CiteScore - Q2 (Oncology)</li> <li class="valid" valid="valid" title="valid: True, node: 194, tag: li, level: 12" node_number="194">Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 3.7 days (median values for papers published in this journal in the first half of 2021).</li> <li class="valid" valid="valid" title="valid: True, node: 195, tag: li, level: 12" node_number="195">Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.</li> <li class="valid" valid="valid" title="valid: True, node: 196, tag: li, level: 12" node_number="196">Sections: published in 14&#160;topical sections.&#160;</li> <li class="valid" valid="valid" title="valid: True, node: 197, tag: li, level: 12" node_number="197">Companion journals for&#160;Cancers include:&#160;<a class="valid" valid="valid" title="valid: True, node: 198, tag: a, level: 13" node_number="198">Radiation</a> and <a class="valid" valid="valid" title="valid: True, node: 199, tag: a, level: 13" node_number="199">Onco</a>.</li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 200, tag: div, level: 10" node_number="200"> Impact Factor: 6.639 (2020) ; 5-Year Impact Factor: 6.999 (2020) </div> <div class="valid" valid="valid" title="valid: True, node: 201, tag: div, level: 10" node_number="201"> <a class="valid" valid="valid" title="valid: True, node: 202, tag: a, level: 11" node_number="202"> <i class="valid" valid="valid" title="valid: True, node: 203, tag: i, level: 12" node_number="203">subject</i> Imprint Information </a> <a class="valid" valid="valid" title="valid: True, node: 204, tag: a, level: 11" node_number="204"> <i class="valid" valid="valid" title="valid: True, node: 205, tag: i, level: 12" node_number="205">get_app</i> Journal Flyer </a> <a class="valid" valid="valid" title="valid: True, node: 206, tag: a, level: 11" node_number="206"> Open Access </a> ISSN: 2072-6694 </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 207, tag: div, level: 7" node_number="207"> <div class="valid" valid="valid" title="valid: True, node: 208, tag: div, level: 8" node_number="208"> <h2 class="valid" valid="valid" title="valid: True, node: 209, tag: h2, level: 9" node_number="209">Latest Articles</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 210, tag: div, level: 8" node_number="210"> <div class="valid" valid="valid" title="valid: True, node: 211, tag: div, level: 9" node_number="211"> <div class="valid" valid="valid" title="valid: True, node: 212, tag: div, level: 10" node_number="212"> <div class="valid" valid="valid" title="valid: True, node: 213, tag: div, level: 11" node_number="213"> <div class="valid" valid="valid" title="valid: True, node: 214, tag: div, level: 12" node_number="214"> <a class="valid" valid="valid" title="valid: True, node: 215, tag: a, level: 13" node_number="215"> <i class="valid" valid="valid" title="valid: True, node: 216, tag: i, level: 14" node_number="216">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 217, tag: div, level: 12" node_number="217"> <a class="valid" valid="valid" title="valid: True, node: 218, tag: a, level: 13" node_number="218"> <i class="valid" valid="valid" title="valid: True, node: 219, tag: i, level: 14" node_number="219">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 220, tag: div, level: 13" node_number="220"> View online as: <a class="valid" valid="valid" title="valid: True, node: 221, tag: a, level: 14" node_number="221">Abstract Page</a> <a class="valid" valid="valid" title="valid: True, node: 222, tag: a, level: 14" node_number="222">Full-Text HTML</a> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 223, tag: div, level: 12" node_number="223">Open AccessReview</div> Therapeutic Targets of KRAS in Colorectal Cancer <div class="valid" valid="valid" title="valid: True, node: 224, tag: div, level: 12" node_number="224"> by <span class="valid" valid="valid" title="valid: True, node: 225, tag: span, level: 13" node_number="225"><div class="valid" valid="valid" title="valid: True, node: 226, tag: div, level: 14" node_number="226">Shafia Rahman</div>, </span><span class="valid" valid="valid" title="valid: True, node: 227, tag: span, level: 13" node_number="227"><div class="valid" valid="valid" title="valid: True, node: 228, tag: div, level: 14" node_number="228">Shimon Garrel</div>, </span><span class="valid" valid="valid" title="valid: True, node: 229, tag: span, level: 13" node_number="229"><div class="valid" valid="valid" title="valid: True, node: 230, tag: div, level: 14" node_number="230">Michael Gerber</div>, </span><span class="valid" valid="valid" title="valid: True, node: 231, tag: span, level: 13" node_number="231"><div class="valid" valid="valid" title="valid: True, node: 232, tag: div, level: 14" node_number="232">Radhashree Maitra</div> and </span><span class="valid" valid="valid" title="valid: True, node: 233, tag: span, level: 13" node_number="233"><div class="valid" valid="valid" title="valid: True, node: 234, tag: div, level: 14" node_number="234">Sanjay Goel</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 235, tag: div, level: 12" node_number="235"> Cancers <b class="valid" valid="valid" title="valid: True, node: 236, tag: b, level: 13" node_number="236">2021</b>, 13(24), 6233; https://doi.org/10.3390/cancers13246233 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 237, tag: div, level: 12" node_number="237"> Abstract <div class="valid" valid="valid" title="valid: True, node: 238, tag: div, level: 13" node_number="238"> Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor <i class="valid" valid="valid" title="valid: True, node: 239, tag: i, level: 14" node_number="239">KRAS</i> mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 240, tag: div, level: 13" node_number="240"> Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor <i class="valid" valid="valid" title="valid: True, node: 241, tag: i, level: 14" node_number="241">KRAS</i> mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with <i class="valid" valid="valid" title="valid: True, node: 242, tag: i, level: 14" node_number="242">KRAS</i>-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting <i class="valid" valid="valid" title="valid: True, node: 243, tag: i, level: 14" node_number="243">KRAS</i>- mutant CRC, while reviewing and elaborating on the discovery and physiology of <i class="valid" valid="valid" title="valid: True, node: 244, tag: i, level: 14" node_number="244">KRAS.</i> Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 245, tag: div, level: 12" node_number="245"> (This article belongs to the Special Issue Targeting KRAS: Elucidating Mechanisms of Sensitivity and Resistance) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 246, tag: div, level: 12" node_number="246"><div class="valid" valid="valid" title="valid: True, node: 247, tag: div, level: 13" node_number="247"><div class="valid" valid="valid" title="valid: True, node: 248, tag: div, level: 14" node_number="248"><p title="valid: False, node: 249, tag: p, level: 15" node_number="249">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 250, tag: div, level: 9" node_number="250"> <div class="valid" valid="valid" title="valid: True, node: 251, tag: div, level: 10" node_number="251"> <div class="valid" valid="valid" title="valid: True, node: 252, tag: div, level: 11" node_number="252"> <div class="valid" valid="valid" title="valid: True, node: 253, tag: div, level: 12" node_number="253"> <div class="valid" valid="valid" title="valid: True, node: 254, tag: div, level: 13" node_number="254"> <a class="valid" valid="valid" title="valid: True, node: 255, tag: a, level: 14" node_number="255"> <i title="valid: False, node: 256, tag: i, level: 15" node_number="256">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 257, tag: div, level: 14" node_number="257"> Supplementary material: Supplementary File 1 (ZIP, 2249 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 258, tag: div, level: 13" node_number="258"> <a class="valid" valid="valid" title="valid: True, node: 259, tag: a, level: 14" node_number="259"> <i title="valid: False, node: 260, tag: i, level: 15" node_number="260">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 261, tag: div, level: 13" node_number="261"> <a class="valid" valid="valid" title="valid: True, node: 262, tag: a, level: 14" node_number="262"> <i title="valid: False, node: 263, tag: i, level: 15" node_number="263">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 264, tag: div, level: 14" node_number="264"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 265, tag: div, level: 13" node_number="265">Open AccessArticle</div> The Antiviral Drug Efavirenz in Breast Cancer Stem Cell Therapy <div class="valid" valid="valid" title="valid: True, node: 266, tag: div, level: 13" node_number="266"> by <span class="valid" valid="valid" title="valid: True, node: 267, tag: span, level: 14" node_number="267"><div title="valid: False, node: 268, tag: div, level: 15" node_number="268">Pey-Tsyr Chiou</div>, </span><span class="valid" valid="valid" title="valid: True, node: 269, tag: span, level: 14" node_number="269"><div title="valid: False, node: 270, tag: div, level: 15" node_number="270">Stephen Ohms</div>, </span><span class="valid" valid="valid" title="valid: True, node: 271, tag: span, level: 14" node_number="271"><div title="valid: False, node: 272, tag: div, level: 15" node_number="272">Philip G. Board</div>, </span><span class="valid" valid="valid" title="valid: True, node: 273, tag: span, level: 14" node_number="273"><div title="valid: False, node: 274, tag: div, level: 15" node_number="274">Jane E. Dahlstrom</div>, </span><span class="valid" valid="valid" title="valid: True, node: 275, tag: span, level: 14" node_number="275"><div title="valid: False, node: 276, tag: div, level: 15" node_number="276">Danny Rangasamy</div> and </span><span class="valid" valid="valid" title="valid: True, node: 277, tag: span, level: 14" node_number="277"><div title="valid: False, node: 278, tag: div, level: 15" node_number="278">Marco G. Casarotto</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 279, tag: div, level: 13" node_number="279"> Cancers <b class="valid" valid="valid" title="valid: True, node: 280, tag: b, level: 14" node_number="280">2021</b>, 13(24), 6232; https://doi.org/10.3390/cancers13246232 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 281, tag: div, level: 13" node_number="281"> Abstract <div class="valid" valid="valid" title="valid: True, node: 282, tag: div, level: 14" node_number="282"> Although many breast cancer therapies show initial success in the treatment of the primary tumour, they often fail to eliminate a sub-population of cells known as cancer stem cells (CSCs). These cells are recognised for their self-renewal properties and for their capacity for [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 283, tag: div, level: 14" node_number="283"> Although many breast cancer therapies show initial success in the treatment of the primary tumour, they often fail to eliminate a sub-population of cells known as cancer stem cells (CSCs). These cells are recognised for their self-renewal properties and for their capacity for differentiation often leading to chemo/radio-resistance. The antiviral drug Efavirenz has been shown to be effective in eliminating triple-negative breast cancer cells, and here we examine its effect on breast CSCs. The effects of Efavirenz on CSCs for several breast cancer cell lines were investigated by examining cellular changes upon drug treatment, including CSC numbers, morphology, RNA/microRNA expression and levels of epithelial/mesenchymal CSC subtypes. Efavirenz treatment resulted in a decrease in the size and number of tumorspheres and a reduction in epithelial-type CSC levels, but an increase in mesenchymal-type CSCs. Efavirenz caused upregulation of several CSC-related genes as well as <i title="valid: False, node: 284, tag: i, level: 15" node_number="284">miR-21</i>, a CSC marker and <i title="valid: False, node: 285, tag: i, level: 15" node_number="285">miR-182</i>, a CSC suppressor gene. We conclude that Efavirenz alters the phenotype and expression of key genes in breast CSCs, which has important potential therapeutic implications. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 286, tag: div, level: 13" node_number="286"> (This article belongs to the Special Issue Understanding and Modelling Metabolic Reprogramming in Breast Cancer) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 287, tag: div, level: 13" node_number="287"><div class="valid" valid="valid" title="valid: True, node: 288, tag: div, level: 14" node_number="288"><div title="valid: False, node: 289, tag: div, level: 15" node_number="289"><p title="valid: False, node: 290, tag: p, level: 16" node_number="290">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 291, tag: div, level: 10" node_number="291"> <div class="valid" valid="valid" title="valid: True, node: 292, tag: div, level: 11" node_number="292"> <div class="valid" valid="valid" title="valid: True, node: 293, tag: div, level: 12" node_number="293"> <div class="valid" valid="valid" title="valid: True, node: 294, tag: div, level: 13" node_number="294"> <a class="valid" valid="valid" title="valid: True, node: 295, tag: a, level: 14" node_number="295"> <i title="valid: False, node: 296, tag: i, level: 15" node_number="296">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 297, tag: div, level: 13" node_number="297"> <a class="valid" valid="valid" title="valid: True, node: 298, tag: a, level: 14" node_number="298"> <i title="valid: False, node: 299, tag: i, level: 15" node_number="299">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 300, tag: div, level: 14" node_number="300"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 301, tag: div, level: 13" node_number="301">Open AccessReview</div> Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment <div class="valid" valid="valid" title="valid: True, node: 302, tag: div, level: 13" node_number="302"> by <span class="valid" valid="valid" title="valid: True, node: 303, tag: span, level: 14" node_number="303"><div title="valid: False, node: 304, tag: div, level: 15" node_number="304">Racheal Louise Johnson</div>, </span><span class="valid" valid="valid" title="valid: True, node: 305, tag: span, level: 14" node_number="305"><div title="valid: False, node: 306, tag: div, level: 15" node_number="306">Michele Cummings</div>, </span><span class="valid" valid="valid" title="valid: True, node: 307, tag: span, level: 14" node_number="307"><div title="valid: False, node: 308, tag: div, level: 15" node_number="308">Amudha Thangavelu</div>, </span><span class="valid" valid="valid" title="valid: True, node: 309, tag: span, level: 14" node_number="309"><div title="valid: False, node: 310, tag: div, level: 15" node_number="310">Georgios Theophilou</div>, </span><span class="valid" valid="valid" title="valid: True, node: 311, tag: span, level: 14" node_number="311"><div title="valid: False, node: 312, tag: div, level: 15" node_number="312">Diederick de Jong</div> and </span><span class="valid" valid="valid" title="valid: True, node: 313, tag: span, level: 14" node_number="313"><div title="valid: False, node: 314, tag: div, level: 15" node_number="314">Nicolas Michel Orsi</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 315, tag: div, level: 13" node_number="315"> Cancers <b class="valid" valid="valid" title="valid: True, node: 316, tag: b, level: 14" node_number="316">2021</b>, 13(24), 6231; https://doi.org/10.3390/cancers13246231 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 317, tag: div, level: 13" node_number="317"> Abstract <div class="valid" valid="valid" title="valid: True, node: 318, tag: div, level: 14" node_number="318"> A lack of explicit early clinical signs and effective screening measures mean that ovarian cancer (OC) often presents as advanced, incurable disease. While conventional treatment combines maximal cytoreductive surgery and platinum-based chemotherapy, patients frequently develop chemoresistance and disease recurrence. The clinical application of [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 319, tag: div, level: 14" node_number="319"> A lack of explicit early clinical signs and effective screening measures mean that ovarian cancer (OC) often presents as advanced, incurable disease. While conventional treatment combines maximal cytoreductive surgery and platinum-based chemotherapy, patients frequently develop chemoresistance and disease recurrence. The clinical application of immune checkpoint blockade (ICB) aims to restore anti-cancer T-cell function in the tumour microenvironment (TME). Disappointingly, even though tumour infiltrating lymphocytes are associated with superior survival in OC, ICB has offered limited therapeutic benefits. Herein, we discuss specific TME features that prevent ICB from reaching its full potential, focussing in particular on the challenges created by immune, genomic and metabolic alterations. We explore both recent and current therapeutic strategies aiming to overcome these hurdles, including the synergistic effect of combination treatments with immune-based strategies and review the status quo of current clinical trials aiming to maximise the success of immunotherapy in OC. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 320, tag: div, level: 13" node_number="320"> (This article belongs to the Special Issue Immunotherapy in Ovarian Cancer) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 321, tag: div, level: 13" node_number="321"><div class="valid" valid="valid" title="valid: True, node: 322, tag: div, level: 14" node_number="322"><div title="valid: False, node: 323, tag: div, level: 15" node_number="323"><p title="valid: False, node: 324, tag: p, level: 16" node_number="324">Graphical abstract</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 325, tag: div, level: 10" node_number="325"> <div class="valid" valid="valid" title="valid: True, node: 326, tag: div, level: 11" node_number="326"> <div class="valid" valid="valid" title="valid: True, node: 327, tag: div, level: 12" node_number="327"> <div class="valid" valid="valid" title="valid: True, node: 328, tag: div, level: 13" node_number="328"> <a class="valid" valid="valid" title="valid: True, node: 329, tag: a, level: 14" node_number="329"> <i title="valid: False, node: 330, tag: i, level: 15" node_number="330">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 331, tag: div, level: 13" node_number="331"> <a class="valid" valid="valid" title="valid: True, node: 332, tag: a, level: 14" node_number="332"> <i title="valid: False, node: 333, tag: i, level: 15" node_number="333">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 334, tag: div, level: 14" node_number="334"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 335, tag: div, level: 13" node_number="335">Open AccessArticle</div> Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse <div class="valid" valid="valid" title="valid: True, node: 336, tag: div, level: 13" node_number="336"> by <span class="valid" valid="valid" title="valid: True, node: 337, tag: span, level: 14" node_number="337"><div title="valid: False, node: 338, tag: div, level: 15" node_number="338">Costanza Chiapponi</div>, </span><span class="valid" valid="valid" title="valid: True, node: 339, tag: span, level: 14" node_number="339"><div title="valid: False, node: 340, tag: div, level: 15" node_number="340">Milan J. M. Hartmann</div>, </span><span class="valid" valid="valid" title="valid: True, node: 341, tag: span, level: 14" node_number="341"><div title="valid: False, node: 342, tag: div, level: 15" node_number="342">Matthias Schmidt</div>, </span><span class="valid" valid="valid" title="valid: True, node: 343, tag: span, level: 14" node_number="343"><div title="valid: False, node: 344, tag: div, level: 15" node_number="344">Michael Faust</div>, </span><span class="valid" valid="valid" title="valid: True, node: 345, tag: span, level: 14" node_number="345"><div title="valid: False, node: 346, tag: div, level: 15" node_number="346">Anne M. Schultheis</div>, </span><span class="valid" valid="valid" title="valid: True, node: 347, tag: span, level: 14" node_number="347"><div title="valid: False, node: 348, tag: div, level: 15" node_number="348">Christiane J. Bruns</div> and </span><span class="valid" valid="valid" title="valid: True, node: 349, tag: span, level: 14" node_number="349"><div title="valid: False, node: 350, tag: div, level: 15" node_number="350">Hakan Alakus</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 351, tag: div, level: 13" node_number="351"> Cancers <b class="valid" valid="valid" title="valid: True, node: 352, tag: b, level: 14" node_number="352">2021</b>, 13(24), 6230; https://doi.org/10.3390/cancers13246230 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 353, tag: div, level: 13" node_number="353"> Abstract <div class="valid" valid="valid" title="valid: True, node: 354, tag: div, level: 14" node_number="354"> Compared to its more common counterpart papillary thyroid cancer (PTC), follicular thyroid cancer (FTC) has a less favorable outcome, due to its higher incidence of distant metastases and advanced stages at diagnosis. Despite radioiodine (RAI) avidity, metastatic FTC often progresses after radioiodine treatment [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 355, tag: div, level: 14" node_number="355"> Compared to its more common counterpart papillary thyroid cancer (PTC), follicular thyroid cancer (FTC) has a less favorable outcome, due to its higher incidence of distant metastases and advanced stages at diagnosis. Despite radioiodine (RAI) avidity, metastatic FTC often progresses after radioiodine treatment (RAIT). We aimed at evaluating the indications and outcomes of surgery for cervical relapse of radioiodine refractory FTC. Patients receiving RAIT between 2005 and 2015 at the University Hospital of Cologne, Germany, were screened. Patients with FTC were identified. Demographics, clinic-pathologic characteristics, treatment, and outcome of patients diagnosed with RAI refractory FTC, who underwent cervical surgery in the course of disease, were analyzed. FTC accounted for 8.8% of all thyroid carcinomas undergoing RAIT. In 35.2% of FTC patients, disease persisted or recurred despite a cumulative mean RAI activity of 18.7 GBq &#177; 11.6 (follow-up 83.5 &#177; 56.7 months). Distant metastases were diagnosed in 75% of these patients, as bone (57.6%), lung (54.6%), and liver metastases (12.1%). Cervical relapse occurred in 63.6% of these patients and was treated in 57.1% with surgery with, and without, external beam radiation therapy (EBRT). Despite surgery and EBRT, in 75% of patients, cervical relapse recurred again. In conclusion, surgery for cervical radioiodine refractory FTC relapse is often performed in metastatic setting. With and without EBRT, cure is rare, although metastases can appear radioiodine avid. Early biological marker and systemic treatments for these patients are still needed. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 356, tag: div, level: 13" node_number="356"> (This article belongs to the Special Issue Updates in Thyroid Cancer Surgery) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 357, tag: div, level: 13" node_number="357"><div class="valid" valid="valid" title="valid: True, node: 358, tag: div, level: 14" node_number="358"><div title="valid: False, node: 359, tag: div, level: 15" node_number="359"><p title="valid: False, node: 360, tag: p, level: 16" node_number="360">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 361, tag: div, level: 10" node_number="361"> <div class="valid" valid="valid" title="valid: True, node: 362, tag: div, level: 11" node_number="362"> <div class="valid" valid="valid" title="valid: True, node: 363, tag: div, level: 12" node_number="363"> <div class="valid" valid="valid" title="valid: True, node: 364, tag: div, level: 13" node_number="364"> <a class="valid" valid="valid" title="valid: True, node: 365, tag: a, level: 14" node_number="365"> <i title="valid: False, node: 366, tag: i, level: 15" node_number="366">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 367, tag: div, level: 13" node_number="367"> <a class="valid" valid="valid" title="valid: True, node: 368, tag: a, level: 14" node_number="368"> <i title="valid: False, node: 369, tag: i, level: 15" node_number="369">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 370, tag: div, level: 14" node_number="370"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 371, tag: div, level: 13" node_number="371">Open AccessReview</div> Cancer Therapy Targeting CD47/SIRP&#945; <div class="valid" valid="valid" title="valid: True, node: 372, tag: div, level: 13" node_number="372"> by <span class="valid" valid="valid" title="valid: True, node: 373, tag: span, level: 14" node_number="373"><div title="valid: False, node: 374, tag: div, level: 15" node_number="374">Nazli Dizman</div> and </span><span class="valid" valid="valid" title="valid: True, node: 375, tag: span, level: 14" node_number="375"><div title="valid: False, node: 376, tag: div, level: 15" node_number="376">Elizabeth I. Buchbinder</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 377, tag: div, level: 13" node_number="377"> Cancers <b class="valid" valid="valid" title="valid: True, node: 378, tag: b, level: 14" node_number="378">2021</b>, 13(24), 6229; https://doi.org/10.3390/cancers13246229 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 379, tag: div, level: 13" node_number="379"> Abstract <div class="valid" valid="valid" title="valid: True, node: 380, tag: div, level: 14" node_number="380"> In the past decade, the field of cancer immunotherapy has rapidly advanced, establishing a crucial role for immune checkpoint blockers in the treatment of a variety of cancer types. In parallel with these remarkable clinical developments, further efforts have focused on ways of [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 381, tag: div, level: 14" node_number="381"> In the past decade, the field of cancer immunotherapy has rapidly advanced, establishing a crucial role for immune checkpoint blockers in the treatment of a variety of cancer types. In parallel with these remarkable clinical developments, further efforts have focused on ways of unleashing adaptive immune responses against cancer. CD47, a cell surface molecule overexpressed by several cancer types that facilitates immune escape from macrophages, dendritic cells and natural killer cells, and its ligand SIRP&#945;, have emerged as potential therapeutic targets. A number of agents directed to CD47/SIRP&#945; have been developed and demonstrated preclinical activity. Early phase clinical trials are investigating CD47/SIRP&#945; directed agents with available data, suggesting safety and preliminary activity. Herein, we provide an overview of the mechanistic rationale of targeting CD47/SIRP&#945; axis and associated clinical evidence. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 382, tag: div, level: 13" node_number="382"> (This article belongs to the Special Issue Targeting Innate Immunity to Treat Cancer) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 383, tag: div, level: 13" node_number="383"><div class="valid" valid="valid" title="valid: True, node: 384, tag: div, level: 14" node_number="384"><div title="valid: False, node: 385, tag: div, level: 15" node_number="385"><p title="valid: False, node: 386, tag: p, level: 16" node_number="386">Graphical abstract</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 387, tag: div, level: 10" node_number="387"> <div class="valid" valid="valid" title="valid: True, node: 388, tag: div, level: 11" node_number="388"> <div class="valid" valid="valid" title="valid: True, node: 389, tag: div, level: 12" node_number="389"> <div class="valid" valid="valid" title="valid: True, node: 390, tag: div, level: 13" node_number="390"> <a class="valid" valid="valid" title="valid: True, node: 391, tag: a, level: 14" node_number="391"> <i title="valid: False, node: 392, tag: i, level: 15" node_number="392">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 393, tag: div, level: 13" node_number="393"> <a class="valid" valid="valid" title="valid: True, node: 394, tag: a, level: 14" node_number="394"> <i title="valid: False, node: 395, tag: i, level: 15" node_number="395">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 396, tag: div, level: 14" node_number="396"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 397, tag: div, level: 13" node_number="397">Open AccessReview</div> Multicellular Effects of STAT3 in Non-Small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities <div class="valid" valid="valid" title="valid: True, node: 398, tag: div, level: 13" node_number="398"> by <span class="valid" valid="valid" title="valid: True, node: 399, tag: span, level: 14" node_number="399"><div title="valid: False, node: 400, tag: div, level: 15" node_number="400">Sagun Parakh</div>, </span><span class="valid" valid="valid" title="valid: True, node: 401, tag: span, level: 14" node_number="401"><div title="valid: False, node: 402, tag: div, level: 15" node_number="402">Matthias Ernst</div> and </span><span class="valid" valid="valid" title="valid: True, node: 403, tag: span, level: 14" node_number="403"><div title="valid: False, node: 404, tag: div, level: 15" node_number="404">Ashleigh R. Poh</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 405, tag: div, level: 13" node_number="405"> Cancers <b class="valid" valid="valid" title="valid: True, node: 406, tag: b, level: 14" node_number="406">2021</b>, 13(24), 6228; https://doi.org/10.3390/cancers13246228 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 407, tag: div, level: 13" node_number="407"> Abstract <div class="valid" valid="valid" title="valid: True, node: 408, tag: div, level: 14" node_number="408"> Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of lung cancer cases. Aberrant activation of the Signal Transducer and Activator of Transcription 3 (STAT3) is frequently observed in NSCLC and is associated with a [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 409, tag: div, level: 14" node_number="409"> Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for 85% of lung cancer cases. Aberrant activation of the Signal Transducer and Activator of Transcription 3 (STAT3) is frequently observed in NSCLC and is associated with a poor prognosis. Pre-clinical studies have revealed an unequivocal role for tumor cell-intrinsic and extrinsic STAT3 signaling in NSCLC by promoting angiogenesis, cell survival, cancer cell stemness, drug resistance, and evasion of anti-tumor immunity. Several STAT3-targeting strategies have also been investigated in pre-clinical models, and include preventing upstream receptor/ligand interactions, promoting the degradation of STAT3 mRNA, and interfering with STAT3 DNA binding. In this review, we discuss the molecular and immunological mechanisms by which persistent STAT3 activation promotes NSCLC development, and the utility of STAT3 as a prognostic and predictive biomarker in NSCLC. We also provide a comprehensive update of STAT3-targeting therapies that are currently undergoing clinical evaluation, and discuss the challenges associated with these treatment modalities in human patients. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 410, tag: div, level: 13" node_number="410"> (This article belongs to the Special Issue Multicellular Effects of STAT3 in the Tumour Microenvironment) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 411, tag: div, level: 10" node_number="411"> <div class="valid" valid="valid" title="valid: True, node: 412, tag: div, level: 11" node_number="412"> <div class="valid" valid="valid" title="valid: True, node: 413, tag: div, level: 12" node_number="413"> <div class="valid" valid="valid" title="valid: True, node: 414, tag: div, level: 13" node_number="414"> <a class="valid" valid="valid" title="valid: True, node: 415, tag: a, level: 14" node_number="415"> <i title="valid: False, node: 416, tag: i, level: 15" node_number="416">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 417, tag: div, level: 13" node_number="417"> <a class="valid" valid="valid" title="valid: True, node: 418, tag: a, level: 14" node_number="418"> <i title="valid: False, node: 419, tag: i, level: 15" node_number="419">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 420, tag: div, level: 14" node_number="420"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 421, tag: div, level: 13" node_number="421">Open AccessReview</div> T Cell Aging in Patients with Colorectal Cancer&#8212;What Do We Know So Far? <div class="valid" valid="valid" title="valid: True, node: 422, tag: div, level: 13" node_number="422"> by <span class="valid" valid="valid" title="valid: True, node: 423, tag: span, level: 14" node_number="423"><div title="valid: False, node: 424, tag: div, level: 15" node_number="424">Oana-Maria Thoma</div>, </span><span class="valid" valid="valid" title="valid: True, node: 425, tag: span, level: 14" node_number="425"><div title="valid: False, node: 426, tag: div, level: 15" node_number="426">Markus F. Neurath</div> and </span><span class="valid" valid="valid" title="valid: True, node: 427, tag: span, level: 14" node_number="427"><div title="valid: False, node: 428, tag: div, level: 15" node_number="428">Maximilian J. Waldner</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 429, tag: div, level: 13" node_number="429"> Cancers <b class="valid" valid="valid" title="valid: True, node: 430, tag: b, level: 14" node_number="430">2021</b>, 13(24), 6227; https://doi.org/10.3390/cancers13246227 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 431, tag: div, level: 13" node_number="431"> Abstract <div class="valid" valid="valid" title="valid: True, node: 432, tag: div, level: 14" node_number="432"> Colorectal cancer (CRC) continues to be one of the most frequently diagnosed types of cancers in the world. CRC is considered to affect mostly elderly patients, and the number of diagnosed cases increases with age. Even though general screening improves outcomes, the overall [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 433, tag: div, level: 14" node_number="433"> Colorectal cancer (CRC) continues to be one of the most frequently diagnosed types of cancers in the world. CRC is considered to affect mostly elderly patients, and the number of diagnosed cases increases with age. Even though general screening improves outcomes, the overall survival and recurrence-free CRC rates in aged individuals are highly dependent on their history of comorbidities. Furthermore, aging is also known to alter the immune system, and especially the adaptive immune T cells. Many studies have emphasized the importance of T cell responses to CRC. Therefore, understanding how age-related changes affect the outcome in CRC patients is crucial. This review focuses on what is so far known about age-related T cell dysfunction in elderly patients with colorectal cancer and how aged T cells can mediate its development. Last, this study describes the advances in basic animal models that have potential to be used to elucidate the role of aged T cells in CRC. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 434, tag: div, level: 13" node_number="434"> (This article belongs to the Special Issue Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 435, tag: div, level: 13" node_number="435"><div class="valid" valid="valid" title="valid: True, node: 436, tag: div, level: 14" node_number="436"><div title="valid: False, node: 437, tag: div, level: 15" node_number="437"><p title="valid: False, node: 438, tag: p, level: 16" node_number="438">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 439, tag: div, level: 10" node_number="439"> <div class="valid" valid="valid" title="valid: True, node: 440, tag: div, level: 11" node_number="440"> <div class="valid" valid="valid" title="valid: True, node: 441, tag: div, level: 12" node_number="441"> <div class="valid" valid="valid" title="valid: True, node: 442, tag: div, level: 13" node_number="442"> <a class="valid" valid="valid" title="valid: True, node: 443, tag: a, level: 14" node_number="443"> <i title="valid: False, node: 444, tag: i, level: 15" node_number="444">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 445, tag: div, level: 13" node_number="445"> <a class="valid" valid="valid" title="valid: True, node: 446, tag: a, level: 14" node_number="446"> <i title="valid: False, node: 447, tag: i, level: 15" node_number="447">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 448, tag: div, level: 14" node_number="448"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 449, tag: div, level: 13" node_number="449">Open AccessReview</div> Insights into the Role of Matrix Metalloproteinases in Precancerous Conditions and in Colorectal Cancer <div class="valid" valid="valid" title="valid: True, node: 450, tag: div, level: 13" node_number="450"> by <span class="valid" valid="valid" title="valid: True, node: 451, tag: span, level: 14" node_number="451"><div title="valid: False, node: 452, tag: div, level: 15" node_number="452">Zahra Pezeshkian</div>, </span><span class="valid" valid="valid" title="valid: True, node: 453, tag: span, level: 14" node_number="453"><div title="valid: False, node: 454, tag: div, level: 15" node_number="454">Stefania Nobili</div>, </span><span class="valid" valid="valid" title="valid: True, node: 455, tag: span, level: 14" node_number="455"><div title="valid: False, node: 456, tag: div, level: 15" node_number="456">Noshad Peyravian</div>, </span><span class="valid" valid="valid" title="valid: True, node: 457, tag: span, level: 14" node_number="457"><div title="valid: False, node: 458, tag: div, level: 15" node_number="458">Bahador Shojaee</div>, </span><span class="valid" valid="valid" title="valid: True, node: 459, tag: span, level: 14" node_number="459"><div title="valid: False, node: 460, tag: div, level: 15" node_number="460">Haniye Nazari</div>, </span><span class="valid" valid="valid" title="valid: True, node: 461, tag: span, level: 14" node_number="461"><div title="valid: False, node: 462, tag: div, level: 15" node_number="462">Hiva Soleimani</div>, </span><span class="valid" valid="valid" title="valid: True, node: 463, tag: span, level: 14" node_number="463"><div title="valid: False, node: 464, tag: div, level: 15" node_number="464">Hamid Asadzadeh-Aghdaei</div>, </span><span class="valid" valid="valid" title="valid: True, node: 465, tag: span, level: 14" node_number="465"><div title="valid: False, node: 466, tag: div, level: 15" node_number="466">Maziar Ashrafian Bonab</div>, </span><span class="valid" valid="valid" title="valid: True, node: 467, tag: span, level: 14" node_number="467"><div title="valid: False, node: 468, tag: div, level: 15" node_number="468">Ehsan Nazemalhosseini-Mojarad</div> and </span><span class="valid" valid="valid" title="valid: True, node: 469, tag: span, level: 14" node_number="469"><div title="valid: False, node: 470, tag: div, level: 15" node_number="470">Enrico Mini</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 471, tag: div, level: 13" node_number="471"> Cancers <b class="valid" valid="valid" title="valid: True, node: 472, tag: b, level: 14" node_number="472">2021</b>, 13(24), 6226; https://doi.org/10.3390/cancers13246226 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 473, tag: div, level: 13" node_number="473"> Abstract <div class="valid" valid="valid" title="valid: True, node: 474, tag: div, level: 14" node_number="474"> Colorectal cancer (CRC) is the third and second cancer for incidence and mortality worldwide, respectively, and is becoming prevalent in developing countries. Most CRCs derive from polyps, especially adenomatous polyps, which can gradually transform into CRC. The family of Matrix Metalloproteinases (MMPs) plays [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 475, tag: div, level: 14" node_number="475"> Colorectal cancer (CRC) is the third and second cancer for incidence and mortality worldwide, respectively, and is becoming prevalent in developing countries. Most CRCs derive from polyps, especially adenomatous polyps, which can gradually transform into CRC. The family of Matrix Metalloproteinases (MMPs) plays a critical role in the initiation and progression of CRC. Prominent MMPs, including MMP-1, MMP-2, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, MMP-14, and MMP-21, have been detected in CRC patients, and the expression of most of them correlates with a poor prognosis. Moreover, many studies have explored the inhibition of MMPs and targeted therapy for CRC, but there is not enough information about the role of MMPs in polyp malignancy. In this review, we discuss the role of MMPs in colorectal cancer and its pathogenesis Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 476, tag: div, level: 13" node_number="476"> (This article belongs to the Special Issue Colorectal Cancers: From Present Problems to Future Solutions) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 477, tag: div, level: 10" node_number="477"> <div class="valid" valid="valid" title="valid: True, node: 478, tag: div, level: 11" node_number="478"> <div class="valid" valid="valid" title="valid: True, node: 479, tag: div, level: 12" node_number="479"> <div class="valid" valid="valid" title="valid: True, node: 480, tag: div, level: 13" node_number="480"> <a class="valid" valid="valid" title="valid: True, node: 481, tag: a, level: 14" node_number="481"> <i title="valid: False, node: 482, tag: i, level: 15" node_number="482">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 483, tag: div, level: 14" node_number="483"> Supplementary material: Supplementary File 1 (ZIP, 786 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 484, tag: div, level: 13" node_number="484"> <a class="valid" valid="valid" title="valid: True, node: 485, tag: a, level: 14" node_number="485"> <i title="valid: False, node: 486, tag: i, level: 15" node_number="486">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 487, tag: div, level: 13" node_number="487"> <a class="valid" valid="valid" title="valid: True, node: 488, tag: a, level: 14" node_number="488"> <i title="valid: False, node: 489, tag: i, level: 15" node_number="489">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 490, tag: div, level: 14" node_number="490"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 491, tag: div, level: 13" node_number="491">Open AccessArticle</div> Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients <div class="valid" valid="valid" title="valid: True, node: 492, tag: div, level: 13" node_number="492"> by <span class="valid" valid="valid" title="valid: True, node: 493, tag: span, level: 14" node_number="493"><div title="valid: False, node: 494, tag: div, level: 15" node_number="494">Du-Bois Asante</div>, </span><span class="valid" valid="valid" title="valid: True, node: 495, tag: span, level: 14" node_number="495"><div title="valid: False, node: 496, tag: div, level: 15" node_number="496">Michael Morici</div>, </span><span class="valid" valid="valid" title="valid: True, node: 497, tag: span, level: 14" node_number="497"><div title="valid: False, node: 498, tag: div, level: 15" node_number="498">Ganendra R. K. A. Mohan</div>, </span><span class="valid" valid="valid" title="valid: True, node: 499, tag: span, level: 14" node_number="499"><div title="valid: False, node: 500, tag: div, level: 15" node_number="500">Emmanuel Acheampong</div>, </span><span class="valid" valid="valid" title="valid: True, node: 501, tag: span, level: 14" node_number="501"><div title="valid: False, node: 502, tag: div, level: 15" node_number="502">Isaac Spencer</div>, </span><span class="valid" valid="valid" title="valid: True, node: 503, tag: span, level: 14" node_number="503"><div title="valid: False, node: 504, tag: div, level: 15" node_number="504">Weitao Lin</div>, </span><span class="valid" valid="valid" title="valid: True, node: 505, tag: span, level: 14" node_number="505"><div title="valid: False, node: 506, tag: div, level: 15" node_number="506">Paula van Miert</div>, </span><span class="valid" valid="valid" title="valid: True, node: 507, tag: span, level: 14" node_number="507"><div title="valid: False, node: 508, tag: div, level: 15" node_number="508">Samantha Gibson</div>, </span><span class="valid" valid="valid" title="valid: True, node: 509, tag: span, level: 14" node_number="509"><div title="valid: False, node: 510, tag: div, level: 15" node_number="510">Aaron B. Beasley</div>, </span><span class="valid" valid="valid" title="valid: True, node: 511, tag: span, level: 14" node_number="511"><div title="valid: False, node: 512, tag: div, level: 15" node_number="512">Melanie Ziman</div>, </span><span class="valid" valid="valid" title="valid: True, node: 513, tag: span, level: 14" node_number="513"><div title="valid: False, node: 514, tag: div, level: 15" node_number="514">Leslie Calapre</div>, </span><span class="valid" valid="valid" title="valid: True, node: 515, tag: span, level: 14" node_number="515"><div title="valid: False, node: 516, tag: div, level: 15" node_number="516">Tarek M. Meniawy</div> and </span><span class="valid" valid="valid" title="valid: True, node: 517, tag: span, level: 14" node_number="517"><div title="valid: False, node: 518, tag: div, level: 15" node_number="518">Elin S. Gray</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 519, tag: div, level: 13" node_number="519"> Cancers <b class="valid" valid="valid" title="valid: True, node: 520, tag: b, level: 14" node_number="520">2021</b>, 13(24), 6225; https://doi.org/10.3390/cancers13246225 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 521, tag: div, level: 13" node_number="521"> Abstract <div class="valid" valid="valid" title="valid: True, node: 522, tag: div, level: 14" node_number="522"> Detection of ovarian cancer (OC) circulating tumour cells (CTCs) is primarily based on targeting epithelial markers, thus failing to detect mesenchymal tumour cells. More importantly, the immune checkpoint inhibitor marker PD-L1 has not been demonstrated on CTCs from OC patients. An antibody staining [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 523, tag: div, level: 14" node_number="523"> Detection of ovarian cancer (OC) circulating tumour cells (CTCs) is primarily based on targeting epithelial markers, thus failing to detect mesenchymal tumour cells. More importantly, the immune checkpoint inhibitor marker PD-L1 has not been demonstrated on CTCs from OC patients. An antibody staining protocol was developed and tested using SKOV-3 and OVCA432 OC cell lines. We targeted epithelial (cytokeratin (CK) and EpCAM), mesenchymal (vimentin), and OC-specific (PAX8) markers for detection of CTCs, and CD45/16 and CD31 were used for the exclusion of white blood and vascular endothelial cells, respectively. PD-L1 was used for CTC characterisation. CTCs were enriched using the Parsortix<sup title="valid: False, node: 524, tag: sup, level: 15" node_number="524">TM</sup> system from 16 OC patients. Results revealed the presence of CTCs in 10 (63%) cases. CTCs were heterogeneous, with 113/157 (72%) cells positive for CK/EpCAM (epithelial marker), 58/157 (37%) positive for vimentin (mesenchymal marker), and 17/157 (11%) for both (hybrid). PAX8 was only found in 11/157 (7%) CTCs. In addition, 62/157 (39%) CTCs were positive for PD-L1. Positivity for PD-L1 was significantly associated with the hybrid phenotype when compared with the epithelial (<i title="valid: False, node: 525, tag: i, level: 15" node_number="525">p </i>= 0.007) and mesenchymal (<i title="valid: False, node: 526, tag: i, level: 15" node_number="526">p </i>= 0.0009) expressing CTCs. Characterisation of CTC phenotypes in relation to clinical outcomes is needed to provide insight into the role that epithelial to mesenchymal plasticity plays in OC and its relationship with PD-L1. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 527, tag: div, level: 13" node_number="527"> (This article belongs to the Topic Advances in Ovarian Cancer Research: From Biology to Therapeutics) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 528, tag: div, level: 10" node_number="528"> <div class="valid" valid="valid" title="valid: True, node: 529, tag: div, level: 11" node_number="529"> <div class="valid" valid="valid" title="valid: True, node: 530, tag: div, level: 12" node_number="530"> <div class="valid" valid="valid" title="valid: True, node: 531, tag: div, level: 13" node_number="531"> <a class="valid" valid="valid" title="valid: True, node: 532, tag: a, level: 14" node_number="532"> <i title="valid: False, node: 533, tag: i, level: 15" node_number="533">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 534, tag: div, level: 14" node_number="534"> Supplementary material: Supplementary File 1 (ZIP, 2530 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 535, tag: div, level: 13" node_number="535"> <a class="valid" valid="valid" title="valid: True, node: 536, tag: a, level: 14" node_number="536"> <i title="valid: False, node: 537, tag: i, level: 15" node_number="537">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 538, tag: div, level: 13" node_number="538"> <a class="valid" valid="valid" title="valid: True, node: 539, tag: a, level: 14" node_number="539"> <i title="valid: False, node: 540, tag: i, level: 15" node_number="540">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 541, tag: div, level: 14" node_number="541"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 542, tag: div, level: 13" node_number="542">Open AccessArticle</div> Mapping the Melanoma Plasma Proteome (MPP) Using Single-Shot Proteomics Interfaced with the WiMT Database <div class="valid" valid="valid" title="valid: True, node: 543, tag: div, level: 13" node_number="543"> by <span class="valid" valid="valid" title="valid: True, node: 544, tag: span, level: 14" node_number="544"><div title="valid: False, node: 545, tag: div, level: 15" node_number="545">Nat&#225;lia Almeida</div>, </span><span class="valid" valid="valid" title="valid: True, node: 546, tag: span, level: 14" node_number="546"><div title="valid: False, node: 547, tag: div, level: 15" node_number="547">Jimmy Rodriguez</div>, </span><span class="valid" valid="valid" title="valid: True, node: 548, tag: span, level: 14" node_number="548"><div title="valid: False, node: 549, tag: div, level: 15" node_number="549">Indira Pla Parada</div>, </span><span class="valid" valid="valid" title="valid: True, node: 550, tag: span, level: 14" node_number="550"><div title="valid: False, node: 551, tag: div, level: 15" node_number="551">Yasset Perez-Riverol</div>, </span><span class="valid" valid="valid" title="valid: True, node: 552, tag: span, level: 14" node_number="552"><div title="valid: False, node: 553, tag: div, level: 15" node_number="553">Nicole Woldmar</div>, </span><span class="valid" valid="valid" title="valid: True, node: 554, tag: span, level: 14" node_number="554"><div title="valid: False, node: 555, tag: div, level: 15" node_number="555">Yonghyo Kim</div>, </span><span class="valid" valid="valid" title="valid: True, node: 556, tag: span, level: 14" node_number="556"><div title="valid: False, node: 557, tag: div, level: 15" node_number="557">Henriett Oskolas</div>, </span><span class="valid" valid="valid" title="valid: True, node: 558, tag: span, level: 14" node_number="558"><div title="valid: False, node: 559, tag: div, level: 15" node_number="559">Lazaro Betancourt</div>, </span><span class="valid" valid="valid" title="valid: True, node: 560, tag: span, level: 14" node_number="560"><div title="valid: False, node: 561, tag: div, level: 15" node_number="561">Jeovanis Gil Vald&#233;s</div>, </span><span class="valid" valid="valid" title="valid: True, node: 562, tag: span, level: 14" node_number="562"><div title="valid: False, node: 563, tag: div, level: 15" node_number="563">K. Barbara Sahlin</div>, </span><span class="valid" valid="valid" title="valid: True, node: 564, tag: span, level: 14" node_number="564"><div title="valid: False, node: 565, tag: div, level: 15" node_number="565">Luciana Pizzatti</div>, </span><span class="valid" valid="valid" title="valid: True, node: 566, tag: span, level: 14" node_number="566"><div title="valid: False, node: 567, tag: div, level: 15" node_number="567">A. Marcell Szasz</div>, </span><span class="valid" valid="valid" title="valid: True, node: 568, tag: span, level: 14" node_number="568"><div title="valid: False, node: 569, tag: div, level: 15" node_number="569">Sarolta K&#225;rp&#225;ti</div>, </span><span class="valid" valid="valid" title="valid: True, node: 570, tag: span, level: 14" node_number="570"><div title="valid: False, node: 571, tag: div, level: 15" node_number="571">Roger Appelqvist</div>, </span><span class="valid" valid="valid" title="valid: True, node: 572, tag: span, level: 14" node_number="572"><div title="valid: False, node: 573, tag: div, level: 15" node_number="573">Johan Malm</div>, </span><span class="valid" valid="valid" title="valid: True, node: 574, tag: span, level: 14" node_number="574"><div title="valid: False, node: 575, tag: div, level: 15" node_number="575">Gilberto B. Domont</div>, </span><span class="valid" valid="valid" title="valid: True, node: 576, tag: span, level: 14" node_number="576"><div title="valid: False, node: 577, tag: div, level: 15" node_number="577">F&#225;bio C. S. Nogueira</div>, </span><span class="valid" valid="valid" title="valid: True, node: 578, tag: span, level: 14" node_number="578"><div title="valid: False, node: 579, tag: div, level: 15" node_number="579">Gy&#246;rgy Marko-Varga</div> and </span><span class="valid" valid="valid" title="valid: True, node: 580, tag: span, level: 14" node_number="580"><div title="valid: False, node: 581, tag: div, level: 15" node_number="581">Aniel Sanchez</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 582, tag: div, level: 13" node_number="582"> Cancers <b class="valid" valid="valid" title="valid: True, node: 583, tag: b, level: 14" node_number="583">2021</b>, 13(24), 6224; https://doi.org/10.3390/cancers13246224 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 584, tag: div, level: 13" node_number="584"> Abstract <div class="valid" valid="valid" title="valid: True, node: 585, tag: div, level: 14" node_number="585"> Plasma analysis by mass spectrometry-based proteomics remains a challenge due to its large dynamic range of 10 orders in magnitude. We created a methodology for protein identification known as Wise MS Transfer (WiMT). Melanoma plasma samples from biobank archives were directly analyzed using [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 586, tag: div, level: 14" node_number="586"> Plasma analysis by mass spectrometry-based proteomics remains a challenge due to its large dynamic range of 10 orders in magnitude. We created a methodology for protein identification known as Wise MS Transfer (WiMT). Melanoma plasma samples from biobank archives were directly analyzed using simple sample preparation. WiMT is based on MS1 features between several MS runs together with custom protein databases for ID generation. This entails a multi-level dynamic protein database with different immunodepletion strategies by applying single-shot proteomics. The highest number of melanoma plasma proteins from undepleted and unfractionated plasma was reported, mapping &gt;1200 proteins from &gt;10,000 protein sequences with confirmed significance scoring. Of these, more than 660 proteins were annotated by WiMT from the resulting ~5800 protein sequences. We could verify 4000 proteins by MS1t analysis from HeLA extracts. The WiMT platform provided an output in which 12 previously well-known candidate markers were identified. We also identified low-abundant proteins with functions related to (i) cell signaling, (ii) immune system regulators, and (iii) proteins regulating folding, sorting, and degradation, as well as (iv) vesicular transport proteins. WiMT holds the potential for use in large-scale screening studies with simple sample preparation, and can lead to the discovery of novel proteins with key melanoma disease functions. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 587, tag: div, level: 13" node_number="587"> (This article belongs to the Special Issue Metastatic Progression of Human Melanoma) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 588, tag: div, level: 10" node_number="588"> <div class="valid" valid="valid" title="valid: True, node: 589, tag: div, level: 11" node_number="589"> <div class="valid" valid="valid" title="valid: True, node: 590, tag: div, level: 12" node_number="590"> <div class="valid" valid="valid" title="valid: True, node: 591, tag: div, level: 13" node_number="591"> <a class="valid" valid="valid" title="valid: True, node: 592, tag: a, level: 14" node_number="592"> <i title="valid: False, node: 593, tag: i, level: 15" node_number="593">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 594, tag: div, level: 13" node_number="594"> <a class="valid" valid="valid" title="valid: True, node: 595, tag: a, level: 14" node_number="595"> <i title="valid: False, node: 596, tag: i, level: 15" node_number="596">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 597, tag: div, level: 14" node_number="597"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 598, tag: div, level: 13" node_number="598">Open AccessReview</div> Function-Preserving Gastrectomy for Early Gastric Cancer <div class="valid" valid="valid" title="valid: True, node: 599, tag: div, level: 13" node_number="599"> by <span class="valid" valid="valid" title="valid: True, node: 600, tag: span, level: 14" node_number="600"><div title="valid: False, node: 601, tag: div, level: 15" node_number="601">Yoshihiro Hiramatsu</div>, </span><span class="valid" valid="valid" title="valid: True, node: 602, tag: span, level: 14" node_number="602"><div title="valid: False, node: 603, tag: div, level: 15" node_number="603">Hirotoshi Kikuchi</div> and </span><span class="valid" valid="valid" title="valid: True, node: 604, tag: span, level: 14" node_number="604"><div title="valid: False, node: 605, tag: div, level: 15" node_number="605">Hiroya Takeuchi</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 606, tag: div, level: 13" node_number="606"> Cancers <b class="valid" valid="valid" title="valid: True, node: 607, tag: b, level: 14" node_number="607">2021</b>, 13(24), 6223; https://doi.org/10.3390/cancers13246223 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 608, tag: div, level: 13" node_number="608"> Abstract <div class="valid" valid="valid" title="valid: True, node: 609, tag: div, level: 14" node_number="609"> Recently, minimally invasive (endoscopic or laparoscopic) treatment for early gastric cancer (EGC) has been widely accepted. However, a standard gastrectomy with radical lymphadenectomy is generally performed in patients with EGC who have no indications for endoscopic resection, and postgastrectomy dysfunction is one of [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 610, tag: div, level: 14" node_number="610"> Recently, minimally invasive (endoscopic or laparoscopic) treatment for early gastric cancer (EGC) has been widely accepted. However, a standard gastrectomy with radical lymphadenectomy is generally performed in patients with EGC who have no indications for endoscopic resection, and postgastrectomy dysfunction is one of the problems of standard gastrectomy. Function-preserving gastrectomy, such as proximal gastrectomy and pylorus-preserving gastrectomy, can be considered when attempting to preserve the patient&#8217;s quality of life (QOL) postoperatively. In addition, sentinel node navigation surgery for EGC has been applied in clinical practice in several prospective studies on function-preserving personalized minimized gastrectomy. In the near future, the sentinel lymph node concept is expected to form the basis for establishing an ideal, personalized, minimally invasive function-preserving treatment for patients with EGC, which will improve their postoperative QOL without compromising their long-term survival. In this review article, we summarize the current status, surgical techniques, and postoperative outcomes of function-preserving gastrectomy for EGC. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 611, tag: div, level: 13" node_number="611"> (This article belongs to the Special Issue Early Gastric Cancer) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 612, tag: div, level: 10" node_number="612"> <div class="valid" valid="valid" title="valid: True, node: 613, tag: div, level: 11" node_number="613"> <div class="valid" valid="valid" title="valid: True, node: 614, tag: div, level: 12" node_number="614"> <div class="valid" valid="valid" title="valid: True, node: 615, tag: div, level: 13" node_number="615"> <a class="valid" valid="valid" title="valid: True, node: 616, tag: a, level: 14" node_number="616"> <i title="valid: False, node: 617, tag: i, level: 15" node_number="617">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 618, tag: div, level: 13" node_number="618"> <a class="valid" valid="valid" title="valid: True, node: 619, tag: a, level: 14" node_number="619"> <i title="valid: False, node: 620, tag: i, level: 15" node_number="620">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 621, tag: div, level: 14" node_number="621"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 622, tag: div, level: 13" node_number="622">Open AccessReview</div> Plant Derived Bioactive Compounds, Their Anti-Cancer Effects and In Silico Approaches as an Alternative Target Treatment Strategy for Breast Cancer: An Updated Overview <div class="valid" valid="valid" title="valid: True, node: 623, tag: div, level: 13" node_number="623"> by <span class="valid" valid="valid" title="valid: True, node: 624, tag: span, level: 14" node_number="624"><div title="valid: False, node: 625, tag: div, level: 15" node_number="625">Vijayakumar Shrihastini</div>, </span><span class="valid" valid="valid" title="valid: True, node: 626, tag: span, level: 14" node_number="626"><div title="valid: False, node: 627, tag: div, level: 15" node_number="627">Pandiyan Muthuramalingam</div>, </span><span class="valid" valid="valid" title="valid: True, node: 628, tag: span, level: 14" node_number="628"><div title="valid: False, node: 629, tag: div, level: 15" node_number="629">Sivakumar Adarshan</div>, </span><span class="valid" valid="valid" title="valid: True, node: 630, tag: span, level: 14" node_number="630"><div title="valid: False, node: 631, tag: div, level: 15" node_number="631">Mariappan Sujitha</div>, </span><span class="valid" valid="valid" title="valid: True, node: 632, tag: span, level: 14" node_number="632"><div title="valid: False, node: 633, tag: div, level: 15" node_number="633">Jen-Tsung Chen</div>, </span><span class="valid" valid="valid" title="valid: True, node: 634, tag: span, level: 14" node_number="634"><div title="valid: False, node: 635, tag: div, level: 15" node_number="635">Hyunsuk Shin</div> and </span><span class="valid" valid="valid" title="valid: True, node: 636, tag: span, level: 14" node_number="636"><div title="valid: False, node: 637, tag: div, level: 15" node_number="637">Manikandan Ramesh</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 638, tag: div, level: 13" node_number="638"> Cancers <b class="valid" valid="valid" title="valid: True, node: 639, tag: b, level: 14" node_number="639">2021</b>, 13(24), 6222; https://doi.org/10.3390/cancers13246222 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 640, tag: div, level: 13" node_number="640"> Abstract <div class="valid" valid="valid" title="valid: True, node: 641, tag: div, level: 14" node_number="641"> Cancer is one of the most common malignant diseases that occur worldwide, among which breast cancer is the second leading cause of death in women. The subtypes are associated with differences in the outcome and were selected for treatments according to the estrogen [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 642, tag: div, level: 14" node_number="642"> Cancer is one of the most common malignant diseases that occur worldwide, among which breast cancer is the second leading cause of death in women. The subtypes are associated with differences in the outcome and were selected for treatments according to the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor. Triple-negative breast cancer, one of the subtypes of breast cancer, is difficult to treat and can even lead to death. If breast cancer is not treated during the initial stages, it may spread to nearby organs, a process called metastasis, through the blood or lymph system. For in vitro studies, MCF-7, MDA-MB-231, MDA-MB-468, and T47B are the most commonly used breast cancer cell lines. Clinically, chemotherapy and radiotherapy are usually expensive and can also cause side effects. To overcome these issues, medicinal plants could be the best alternative for chemotherapeutic drugs with fewer side effects and cost-effectiveness. Furthermore, the genes involved in breast cancer can be regulated and synergized with signaling molecules to suppress the proliferation of breast cancer cells. In addition, nanoparticles encapsulating (nano-encapsulation) medicinal plant extracts showed a significant reduction in the apoptotic and cytotoxic activities of breast cancer cells. This present review mainly speculates an overview of the native medicinal plant derived anti-cancerous compounds with its efficiency, types and pathways involved in breast cancer along with its genes, the mechanism of breast cancer brain metastasis, chemoresistivity and its mechanism, bioinformatics approaches which could be an effective alternative for drug discovery. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 643, tag: div, level: 13" node_number="643"> (This article belongs to the Special Issue Plant-Derived Targeted Strategies in Cancer) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 644, tag: div, level: 10" node_number="644"> <div class="valid" valid="valid" title="valid: True, node: 645, tag: div, level: 11" node_number="645"> <div class="valid" valid="valid" title="valid: True, node: 646, tag: div, level: 12" node_number="646"> <div class="valid" valid="valid" title="valid: True, node: 647, tag: div, level: 13" node_number="647"> <a class="valid" valid="valid" title="valid: True, node: 648, tag: a, level: 14" node_number="648"> <i title="valid: False, node: 649, tag: i, level: 15" node_number="649">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 650, tag: div, level: 14" node_number="650"> Supplementary material: Supplementary File 1 (ZIP, 1692 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 651, tag: div, level: 13" node_number="651"> <a class="valid" valid="valid" title="valid: True, node: 652, tag: a, level: 14" node_number="652"> <i title="valid: False, node: 653, tag: i, level: 15" node_number="653">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 654, tag: div, level: 13" node_number="654"> <a class="valid" valid="valid" title="valid: True, node: 655, tag: a, level: 14" node_number="655"> <i title="valid: False, node: 656, tag: i, level: 15" node_number="656">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 657, tag: div, level: 14" node_number="657"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 658, tag: div, level: 13" node_number="658">Open AccessArticle</div> Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma <div class="valid" valid="valid" title="valid: True, node: 659, tag: div, level: 13" node_number="659"> by <span class="valid" valid="valid" title="valid: True, node: 660, tag: span, level: 14" node_number="660"><div title="valid: False, node: 661, tag: div, level: 15" node_number="661">Carolin Sauter-Meyerhoff</div>, </span><span class="valid" valid="valid" title="valid: True, node: 662, tag: span, level: 14" node_number="662"><div title="valid: False, node: 663, tag: div, level: 15" node_number="663">Regina Bohnert</div>, </span><span class="valid" valid="valid" title="valid: True, node: 664, tag: span, level: 14" node_number="664"><div title="valid: False, node: 665, tag: div, level: 15" node_number="665">Pascale Mazzola</div>, </span><span class="valid" valid="valid" title="valid: True, node: 666, tag: span, level: 14" node_number="666"><div title="valid: False, node: 667, tag: div, level: 15" node_number="667">Viktoria St&#252;hler</div>, </span><span class="valid" valid="valid" title="valid: True, node: 668, tag: span, level: 14" node_number="668"><div title="valid: False, node: 669, tag: div, level: 15" node_number="669">Siarhei Kandabarau</div>, </span><span class="valid" valid="valid" title="valid: True, node: 670, tag: span, level: 14" node_number="670"><div title="valid: False, node: 671, tag: div, level: 15" node_number="671">Florian A. B&#252;ttner</div>, </span><span class="valid" valid="valid" title="valid: True, node: 672, tag: span, level: 14" node_number="672"><div title="valid: False, node: 673, tag: div, level: 15" node_number="673">Stefan Winter</div>, </span><span class="valid" valid="valid" title="valid: True, node: 674, tag: span, level: 14" node_number="674"><div title="valid: False, node: 675, tag: div, level: 15" node_number="675">Lisa Herrmann</div>, </span><span class="valid" valid="valid" title="valid: True, node: 676, tag: span, level: 14" node_number="676"><div title="valid: False, node: 677, tag: div, level: 15" node_number="677">Steffen Rausch</div>, </span><span class="valid" valid="valid" title="valid: True, node: 678, tag: span, level: 14" node_number="678"><div title="valid: False, node: 679, tag: div, level: 15" node_number="679">J&#246;rg Hennenlotter</div>, </span><span class="valid" valid="valid" title="valid: True, node: 680, tag: span, level: 14" node_number="680"><div title="valid: False, node: 681, tag: div, level: 15" node_number="681">Falko Fend</div>, </span><span class="valid" valid="valid" title="valid: True, node: 682, tag: span, level: 14" node_number="682"><div title="valid: False, node: 683, tag: div, level: 15" node_number="683">Marcus Scharpf</div>, </span><span class="valid" valid="valid" title="valid: True, node: 684, tag: span, level: 14" node_number="684"><div title="valid: False, node: 685, tag: div, level: 15" node_number="685">Arnulf Stenzl</div>, </span><span class="valid" valid="valid" title="valid: True, node: 686, tag: span, level: 14" node_number="686"><div title="valid: False, node: 687, tag: div, level: 15" node_number="687">Stephan Ossowski</div>, </span><span class="valid" valid="valid" title="valid: True, node: 688, tag: span, level: 14" node_number="688"><div title="valid: False, node: 689, tag: div, level: 15" node_number="689">Jens Bedke</div>, </span><span class="valid" valid="valid" title="valid: True, node: 690, tag: span, level: 14" node_number="690"><div title="valid: False, node: 691, tag: div, level: 15" node_number="691">Matthias Schwab</div> and </span><span class="valid" valid="valid" title="valid: True, node: 692, tag: span, level: 14" node_number="692"><div title="valid: False, node: 693, tag: div, level: 15" node_number="693">Elke Schaeffeler</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 694, tag: div, level: 13" node_number="694"> Cancers <b class="valid" valid="valid" title="valid: True, node: 695, tag: b, level: 14" node_number="695">2021</b>, 13(24), 6221; https://doi.org/10.3390/cancers13246221 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 696, tag: div, level: 13" node_number="696"> Abstract <div class="valid" valid="valid" title="valid: True, node: 697, tag: div, level: 14" node_number="697"> Metastatic renal cell carcinoma (RCC) exhibits poor prognosis. Better knowledge of distant metastases is crucial to foster personalized treatment strategies. Here, we aimed to investigate the genetic landscape of metastases, including synchronous and/or recurrent metastases to elucidate potential drug target genes and clinically [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 698, tag: div, level: 14" node_number="698"> Metastatic renal cell carcinoma (RCC) exhibits poor prognosis. Better knowledge of distant metastases is crucial to foster personalized treatment strategies. Here, we aimed to investigate the genetic landscape of metastases, including synchronous and/or recurrent metastases to elucidate potential drug target genes and clinically relevant mutations in a real-world setting of patients. We assessed 81 metastases from 56 RCC patients, including synchronous and/or recurrent metastases of 19 patients. Samples were analysed through next-generation sequencing with a high coverage (~1000&#215; mean coverage). We therefore established a novel sequencing panel comprising 32 genes with impact on RCC development. We observed a high frequency of mutations in known RCC driver genes (e.g., &gt;40% carriers of <i title="valid: False, node: 699, tag: i, level: 15" node_number="699">VHL</i> and <i title="valid: False, node: 700, tag: i, level: 15" node_number="700">PBRM1</i> mutations) in metastases irrespective of the metastatic site. The somatic mutational composition was significantly associated with cancer-specific survival (<i title="valid: False, node: 701, tag: i, level: 15" node_number="701">p</i>(logrank) = 0.03). Moreover, we identified in 34 patients at least one drug target gene as well as clinically relevant mutations listed in the VICC Meta-Knowledgebase in 7%. In addition to significantly higher mutational burden in recurrent metastases compared to earlier ones, synchronous and/or recurrent metastases of individual patients, even after a time-period &gt;2 yrs, shared a high proportion of somatic events. Our data demonstrate the importance of somatic profiling in metastases for precision medicine in RCC. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 702, tag: div, level: 13" node_number="702"> (This article belongs to the Special Issue Metastatic Renal Cell Carcinoma &#8211; from Diagnosis to Therapy) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 703, tag: div, level: 13" node_number="703"><div class="valid" valid="valid" title="valid: True, node: 704, tag: div, level: 14" node_number="704"><div title="valid: False, node: 705, tag: div, level: 15" node_number="705"><p title="valid: False, node: 706, tag: p, level: 16" node_number="706">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 707, tag: div, level: 10" node_number="707"> <div class="valid" valid="valid" title="valid: True, node: 708, tag: div, level: 11" node_number="708"> <div class="valid" valid="valid" title="valid: True, node: 709, tag: div, level: 12" node_number="709"> <div class="valid" valid="valid" title="valid: True, node: 710, tag: div, level: 13" node_number="710"> <a class="valid" valid="valid" title="valid: True, node: 711, tag: a, level: 14" node_number="711"> <i title="valid: False, node: 712, tag: i, level: 15" node_number="712">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 713, tag: div, level: 14" node_number="713"> Supplementary material: Supplementary File 1 (ZIP, 1093 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 714, tag: div, level: 13" node_number="714"> <a class="valid" valid="valid" title="valid: True, node: 715, tag: a, level: 14" node_number="715"> <i title="valid: False, node: 716, tag: i, level: 15" node_number="716">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 717, tag: div, level: 13" node_number="717"> <a class="valid" valid="valid" title="valid: True, node: 718, tag: a, level: 14" node_number="718"> <i title="valid: False, node: 719, tag: i, level: 15" node_number="719">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 720, tag: div, level: 14" node_number="720"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 721, tag: div, level: 13" node_number="721">Open AccessArticle</div> Nucleolar Stress Functions Upstream to Stimulate Expression of Autophagy Regulators <div class="valid" valid="valid" title="valid: True, node: 722, tag: div, level: 13" node_number="722"> by <span class="valid" valid="valid" title="valid: True, node: 723, tag: span, level: 14" node_number="723"><div title="valid: False, node: 724, tag: div, level: 15" node_number="724">David P. P. Dannheisig</div>, </span><span class="valid" valid="valid" title="valid: True, node: 725, tag: span, level: 14" node_number="725"><div title="valid: False, node: 726, tag: div, level: 15" node_number="726">Anna Schimansky</div>, </span><span class="valid" valid="valid" title="valid: True, node: 727, tag: span, level: 14" node_number="727"><div title="valid: False, node: 728, tag: div, level: 15" node_number="728">Cornelia Donow</div> and </span><span class="valid" valid="valid" title="valid: True, node: 729, tag: span, level: 14" node_number="729"><div title="valid: False, node: 730, tag: div, level: 15" node_number="730">Astrid S. S. Pfister</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 731, tag: div, level: 13" node_number="731"> Cancers <b class="valid" valid="valid" title="valid: True, node: 732, tag: b, level: 14" node_number="732">2021</b>, 13(24), 6220; https://doi.org/10.3390/cancers13246220 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 733, tag: div, level: 13" node_number="733"> Abstract <div class="valid" valid="valid" title="valid: True, node: 734, tag: div, level: 14" node_number="734"> <b title="valid: False, node: 735, tag: b, level: 15" node_number="735"> </b>Ribosome biogenesis is essential for protein synthesis, cell growth and survival. The process takes places in nucleoli and is orchestrated by various proteins, among them RNA polymerases I&#8211;III as well as ribosome biogenesis factors. Perturbation of ribosome biogenesis activates the nucleolar stress response, [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 736, tag: div, level: 14" node_number="736"> <b title="valid: False, node: 737, tag: b, level: 15" node_number="737"> </b>Ribosome biogenesis is essential for protein synthesis, cell growth and survival. The process takes places in nucleoli and is orchestrated by various proteins, among them RNA polymerases I&#8211;III as well as ribosome biogenesis factors. Perturbation of ribosome biogenesis activates the nucleolar stress response, which classically triggers cell cycle arrest and apoptosis. Nucleolar stress is utilized in modern anti-cancer therapies, however, also contributes to the development of various pathologies, including cancer. Growing evidence suggests that nucleolar stress stimulates compensatory cascades, for instance bulk autophagy. However, underlying mechanisms are poorly understood. Here we demonstrate that induction of nucleolar stress activates expression of key autophagic regulators such as <i title="valid: False, node: 738, tag: i, level: 15" node_number="738">ATG7</i> and <i title="valid: False, node: 739, tag: i, level: 15" node_number="739">ATG16L1</i>, essential for generation of autophagosomes. We show that knockdown of the ribosomopathy factor SBDS, or of key ribosome biogenesis factors (PPAN, NPM, PES1) is associated with enhanced levels of ATG7 in cancer cells. The same holds true when interfering with RNA polymerase I function by either pharmacological inhibition (CX5461) or depletion of the transcription factor UBF1. Moreover, we demonstrate that RNA pol&#160;I inhibition by CX-5461 stimulates autophagic flux. Together, our data establish that nucleolar stress affects transcriptional regulation of autophagy. Given the contribution of both axes in propagation or cure of cancer, our data uncover a connection that might be targeted in future. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 740, tag: div, level: 13" node_number="740"> (This article belongs to the Special Issue Protein Synthesis in Cancer Cells: Mechanisms and Novel Targeted Therapies) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 741, tag: div, level: 10" node_number="741"> <div class="valid" valid="valid" title="valid: True, node: 742, tag: div, level: 11" node_number="742"> <div class="valid" valid="valid" title="valid: True, node: 743, tag: div, level: 12" node_number="743"> <div class="valid" valid="valid" title="valid: True, node: 744, tag: div, level: 13" node_number="744"> <a class="valid" valid="valid" title="valid: True, node: 745, tag: a, level: 14" node_number="745"> <i title="valid: False, node: 746, tag: i, level: 15" node_number="746">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 747, tag: div, level: 13" node_number="747"> <a class="valid" valid="valid" title="valid: True, node: 748, tag: a, level: 14" node_number="748"> <i title="valid: False, node: 749, tag: i, level: 15" node_number="749">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 750, tag: div, level: 14" node_number="750"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 751, tag: div, level: 13" node_number="751">Open AccessReview</div> Shooting at Moving and Hidden Targets&#8212;Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas <div class="valid" valid="valid" title="valid: True, node: 752, tag: div, level: 13" node_number="752"> by <span class="valid" valid="valid" title="valid: True, node: 753, tag: span, level: 14" node_number="753"><div title="valid: False, node: 754, tag: div, level: 15" node_number="754">Joanna Ka&#322;afut</div>, </span><span class="valid" valid="valid" title="valid: True, node: 755, tag: span, level: 14" node_number="755"><div title="valid: False, node: 756, tag: div, level: 15" node_number="756">Arkadiusz Czerwonka</div>, </span><span class="valid" valid="valid" title="valid: True, node: 757, tag: span, level: 14" node_number="757"><div title="valid: False, node: 758, tag: div, level: 15" node_number="758">Alinda Anameri&#231;</div>, </span><span class="valid" valid="valid" title="valid: True, node: 759, tag: span, level: 14" node_number="759"><div title="valid: False, node: 760, tag: div, level: 15" node_number="760">Alicja Przybyszewska-Podstawka</div>, </span><span class="valid" valid="valid" title="valid: True, node: 761, tag: span, level: 14" node_number="761"><div title="valid: False, node: 762, tag: div, level: 15" node_number="762">Julia O. Misiorek</div>, </span><span class="valid" valid="valid" title="valid: True, node: 763, tag: span, level: 14" node_number="763"><div title="valid: False, node: 764, tag: div, level: 15" node_number="764">Adolfo Rivero-M&#252;ller</div> and </span><span class="valid" valid="valid" title="valid: True, node: 765, tag: span, level: 14" node_number="765"><div title="valid: False, node: 766, tag: div, level: 15" node_number="766">Matthias Nees</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 767, tag: div, level: 13" node_number="767"> Cancers <b class="valid" valid="valid" title="valid: True, node: 768, tag: b, level: 14" node_number="768">2021</b>, 13(24), 6219; https://doi.org/10.3390/cancers13246219 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 769, tag: div, level: 13" node_number="769"> Abstract <div class="valid" valid="valid" title="valid: True, node: 770, tag: div, level: 14" node_number="770"> Head and Neck Squamous Cell Carcinoma (HNSCC) is often aggressive, with poor response to current therapies in approximately 40&#8211;50% of the patients. Current therapies are restricted to operation and irradiation, often combined with a small number of standard-of-care chemotherapeutic drugs, preferentially for advanced [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 771, tag: div, level: 14" node_number="771"> Head and Neck Squamous Cell Carcinoma (HNSCC) is often aggressive, with poor response to current therapies in approximately 40&#8211;50% of the patients. Current therapies are restricted to operation and irradiation, often combined with a small number of standard-of-care chemotherapeutic drugs, preferentially for advanced tumour patients. Only very recently, newer targeted therapies have entered the clinics, including Cetuximab, which targets the EGF receptor (EGFR), and several immune checkpoint inhibitors targeting the immune receptor PD-1 and its ligand PD-L1. HNSCC tumour tissues are characterized by a high degree of intra-tumour heterogeneity (ITH), and non-genetic alterations that may affect both non-transformed cells, such as cancer-associated fibroblasts (CAFs), and transformed carcinoma cells. This very high degree of heterogeneity likely contributes to acquired drug resistance, tumour dormancy, relapse, and distant or lymph node metastasis. ITH, in turn, is likely promoted by pronounced tumour cell plasticity, which manifests in highly dynamic and reversible phenomena such as of partial or hybrid forms of epithelial-to-mesenchymal transition (EMT), and enhanced tumour stemness. Stemness and tumour cell plasticity are strongly promoted by Notch signalling, which remains poorly understood especially in HNSCC. Here, we aim to elucidate how Notch signal may act both as a tumour suppressor and proto-oncogenic, probably during different stages of tumour cell initiation and progression. Notch signalling also interacts with numerous other signalling pathways, that may also have a decisive impact on tumour cell plasticity, acquired radio/chemoresistance, and metastatic progression of HNSCC. We outline the current stage of research related to Notch signalling, and how this pathway may be intricately interconnected with other, druggable targets and signalling mechanisms in HNSCC. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 772, tag: div, level: 13" node_number="772"> (This article belongs to the Special Issue Molecular Targets for Head and Neck Cancer) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 773, tag: div, level: 10" node_number="773"> <div class="valid" valid="valid" title="valid: True, node: 774, tag: div, level: 11" node_number="774"> <div class="valid" valid="valid" title="valid: True, node: 775, tag: div, level: 12" node_number="775"> <div class="valid" valid="valid" title="valid: True, node: 776, tag: div, level: 13" node_number="776"> <a class="valid" valid="valid" title="valid: True, node: 777, tag: a, level: 14" node_number="777"> <i title="valid: False, node: 778, tag: i, level: 15" node_number="778">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 779, tag: div, level: 13" node_number="779"> <a class="valid" valid="valid" title="valid: True, node: 780, tag: a, level: 14" node_number="780"> <i title="valid: False, node: 781, tag: i, level: 15" node_number="781">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 782, tag: div, level: 14" node_number="782"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 783, tag: div, level: 13" node_number="783">Open AccessReview</div> Molecular Classification and Therapeutic Targets in Ependymoma <div class="valid" valid="valid" title="valid: True, node: 784, tag: div, level: 13" node_number="784"> by <span class="valid" valid="valid" title="valid: True, node: 785, tag: span, level: 14" node_number="785"><div title="valid: False, node: 786, tag: div, level: 15" node_number="786">Thomas Larrew</div>, </span><span class="valid" valid="valid" title="valid: True, node: 787, tag: span, level: 14" node_number="787"><div title="valid: False, node: 788, tag: div, level: 15" node_number="788">Brian Fabian Saway</div>, </span><span class="valid" valid="valid" title="valid: True, node: 789, tag: span, level: 14" node_number="789"><div title="valid: False, node: 790, tag: div, level: 15" node_number="790">Stephen R. Lowe</div> and </span><span class="valid" valid="valid" title="valid: True, node: 791, tag: span, level: 14" node_number="791"><div title="valid: False, node: 792, tag: div, level: 15" node_number="792">Adriana Olar</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 793, tag: div, level: 13" node_number="793"> Cancers <b class="valid" valid="valid" title="valid: True, node: 794, tag: b, level: 14" node_number="794">2021</b>, 13(24), 6218; https://doi.org/10.3390/cancers13246218 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 795, tag: div, level: 13" node_number="795"> Abstract <div class="valid" valid="valid" title="valid: True, node: 796, tag: div, level: 14" node_number="796"> Ependymoma is a biologically diverse tumor wherein molecular classification has superseded traditional histological grading based on its superior ability to characterize behavior, prognosis, and possible targeted therapies. The current, updated molecular classification of ependymoma consists of ten distinct subgroups spread evenly among the [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 797, tag: div, level: 14" node_number="797"> Ependymoma is a biologically diverse tumor wherein molecular classification has superseded traditional histological grading based on its superior ability to characterize behavior, prognosis, and possible targeted therapies. The current, updated molecular classification of ependymoma consists of ten distinct subgroups spread evenly among the spinal, infratentorial, and supratentorial compartments, each with its own distinct clinical and molecular characteristics. In this review, the history, histopathology, standard of care, prognosis, oncogenic drivers, and hypothesized molecular targets for all subgroups of ependymoma are explored. This review emphasizes that despite the varied behavior of the ependymoma subgroups, it remains clear that research must be performed to further elucidate molecular targets for these tumors. Although not all ependymoma subgroups are oncologically aggressive, development of targeted therapies is essential, particularly for cases where surgical resection is not an option without causing significant morbidity. The development of molecular therapies must rely on building upon our current understanding of ependymoma oncogenesis, as well as cultivating transfer of knowledge based on malignancies with similar genomic alterations. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 798, tag: div, level: 13" node_number="798"> (This article belongs to the Special Issue Updates on Molecular Targeted Therapies for CNS Tumors) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 799, tag: div, level: 13" node_number="799"><div class="valid" valid="valid" title="valid: True, node: 800, tag: div, level: 14" node_number="800"><div title="valid: False, node: 801, tag: div, level: 15" node_number="801"><p title="valid: False, node: 802, tag: p, level: 16" node_number="802">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 803, tag: div, level: 10" node_number="803"> <div class="valid" valid="valid" title="valid: True, node: 804, tag: div, level: 11" node_number="804"> <div class="valid" valid="valid" title="valid: True, node: 805, tag: div, level: 12" node_number="805"> <div class="valid" valid="valid" title="valid: True, node: 806, tag: div, level: 13" node_number="806"> <a class="valid" valid="valid" title="valid: True, node: 807, tag: a, level: 14" node_number="807"> <i title="valid: False, node: 808, tag: i, level: 15" node_number="808">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 809, tag: div, level: 13" node_number="809"> <a class="valid" valid="valid" title="valid: True, node: 810, tag: a, level: 14" node_number="810"> <i title="valid: False, node: 811, tag: i, level: 15" node_number="811">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 812, tag: div, level: 14" node_number="812"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 813, tag: div, level: 13" node_number="813">Open AccessReview</div> Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy <div class="valid" valid="valid" title="valid: True, node: 814, tag: div, level: 13" node_number="814"> by <span class="valid" valid="valid" title="valid: True, node: 815, tag: span, level: 14" node_number="815"><div title="valid: False, node: 816, tag: div, level: 15" node_number="816">Valentina Aleotti</div>, </span><span class="valid" valid="valid" title="valid: True, node: 817, tag: span, level: 14" node_number="817"><div title="valid: False, node: 818, tag: div, level: 15" node_number="818">Cristina Catoni</div>, </span><span class="valid" valid="valid" title="valid: True, node: 819, tag: span, level: 14" node_number="819"><div title="valid: False, node: 820, tag: div, level: 15" node_number="820">Cristina Poggiana</div>, </span><span class="valid" valid="valid" title="valid: True, node: 821, tag: span, level: 14" node_number="821"><div title="valid: False, node: 822, tag: div, level: 15" node_number="822">Antonio Rosato</div>, </span><span class="valid" valid="valid" title="valid: True, node: 823, tag: span, level: 14" node_number="823"><div title="valid: False, node: 824, tag: div, level: 15" node_number="824">Antonella Facchinetti</div> and </span><span class="valid" valid="valid" title="valid: True, node: 825, tag: span, level: 14" node_number="825"><div title="valid: False, node: 826, tag: div, level: 15" node_number="826">Maria Chiara Scaini</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 827, tag: div, level: 13" node_number="827"> Cancers <b class="valid" valid="valid" title="valid: True, node: 828, tag: b, level: 14" node_number="828">2021</b>, 13(24), 6217; https://doi.org/10.3390/cancers13246217 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 829, tag: div, level: 13" node_number="829"> Abstract <div class="valid" valid="valid" title="valid: True, node: 830, tag: div, level: 14" node_number="830"> Malignant melanoma is the most serious, life-threatening form of all dermatologic diseases, with a poor prognosis in the presence of metastases and advanced disease. Despite recent advances in targeted therapy and immunotherapy, there is still a critical need for a better understanding of [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 831, tag: div, level: 14" node_number="831"> Malignant melanoma is the most serious, life-threatening form of all dermatologic diseases, with a poor prognosis in the presence of metastases and advanced disease. Despite recent advances in targeted therapy and immunotherapy, there is still a critical need for a better understanding of the fundamental mechanisms behind melanoma progression and resistance onset. Recent advances in genome-wide methylation methods have revealed that aberrant changes in the pattern of DNA methylation play an important role in many aspects of cancer progression, including cell proliferation and migration, evasion of cell death, invasion, and metastasization. The purpose of the current review was to gather evidence regarding the usefulness of DNA methylation tracking in liquid biopsy as a potential biomarker in melanoma. We investigated the key genes and signal transduction pathways that have been found to be altered epigenetically in melanoma. We then highlighted the circulating tumor components present in blood, including circulating melanoma cells (CMC), circulating tumor DNA (ctDNA), and tumor-derived extracellular vesicles (EVs), as a valuable source for identifying relevant aberrations in DNA methylation. Finally, we focused on DNA methylation signatures as a marker for tracking response to therapy and resistance, thus facilitating personalized medicine and decision-making in the treatment of melanoma patients. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 832, tag: div, level: 13" node_number="832"> (This article belongs to the Special Issue DNA Methylation Markers in Liquid Biopsies) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 833, tag: div, level: 13" node_number="833"><div class="valid" valid="valid" title="valid: True, node: 834, tag: div, level: 14" node_number="834"><div title="valid: False, node: 835, tag: div, level: 15" node_number="835"><p title="valid: False, node: 836, tag: p, level: 16" node_number="836">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 837, tag: div, level: 10" node_number="837"> <div class="valid" valid="valid" title="valid: True, node: 838, tag: div, level: 11" node_number="838"> <div class="valid" valid="valid" title="valid: True, node: 839, tag: div, level: 12" node_number="839"> <div class="valid" valid="valid" title="valid: True, node: 840, tag: div, level: 13" node_number="840"> <a class="valid" valid="valid" title="valid: True, node: 841, tag: a, level: 14" node_number="841"> <i title="valid: False, node: 842, tag: i, level: 15" node_number="842">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 843, tag: div, level: 14" node_number="843"> Supplementary material: Supplementary File 1 (ZIP, 36 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 844, tag: div, level: 13" node_number="844"> <a class="valid" valid="valid" title="valid: True, node: 845, tag: a, level: 14" node_number="845"> <i title="valid: False, node: 846, tag: i, level: 15" node_number="846">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 847, tag: div, level: 13" node_number="847"> <a class="valid" valid="valid" title="valid: True, node: 848, tag: a, level: 14" node_number="848"> <i title="valid: False, node: 849, tag: i, level: 15" node_number="849">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 850, tag: div, level: 14" node_number="850"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 851, tag: div, level: 13" node_number="851">Open AccessArticle</div> Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer <div class="valid" valid="valid" title="valid: True, node: 852, tag: div, level: 13" node_number="852"> by <span class="valid" valid="valid" title="valid: True, node: 853, tag: span, level: 14" node_number="853"><div title="valid: False, node: 854, tag: div, level: 15" node_number="854">Koldo Garcia-Etxebarria</div>, </span><span class="valid" valid="valid" title="valid: True, node: 855, tag: span, level: 14" node_number="855"><div title="valid: False, node: 856, tag: div, level: 15" node_number="856">Marc Clos-Garcia</div>, </span><span class="valid" valid="valid" title="valid: True, node: 857, tag: span, level: 14" node_number="857"><div title="valid: False, node: 858, tag: div, level: 15" node_number="858">Oiana Telleria</div>, </span><span class="valid" valid="valid" title="valid: True, node: 859, tag: span, level: 14" node_number="859"><div title="valid: False, node: 860, tag: div, level: 15" node_number="860">Beatriz Nafr&#237;a</div>, </span><span class="valid" valid="valid" title="valid: True, node: 861, tag: span, level: 14" node_number="861"><div title="valid: False, node: 862, tag: div, level: 15" node_number="862">Cristina Alonso</div>, </span><span class="valid" valid="valid" title="valid: True, node: 863, tag: span, level: 14" node_number="863"><div title="valid: False, node: 864, tag: div, level: 15" node_number="864">Marta Iruarrizaga-Lejarreta</div>, </span><span class="valid" valid="valid" title="valid: True, node: 865, tag: span, level: 14" node_number="865"><div title="valid: False, node: 866, tag: div, level: 15" node_number="866">Andre Franke</div>, </span><span class="valid" valid="valid" title="valid: True, node: 867, tag: span, level: 14" node_number="867"><div title="valid: False, node: 868, tag: div, level: 15" node_number="868">Anais Crespo</div>, </span><span class="valid" valid="valid" title="valid: True, node: 869, tag: span, level: 14" node_number="869"><div title="valid: False, node: 870, tag: div, level: 15" node_number="870">Agueda Iglesias</div>, </span><span class="valid" valid="valid" title="valid: True, node: 871, tag: span, level: 14" node_number="871"><div title="valid: False, node: 872, tag: div, level: 15" node_number="872">Joaqu&#237;n Cubiella</div>, </span><span class="valid" valid="valid" title="valid: True, node: 873, tag: span, level: 14" node_number="873"><div title="valid: False, node: 874, tag: div, level: 15" node_number="874">Luis Bujanda</div> and </span><span class="valid" valid="valid" title="valid: True, node: 875, tag: span, level: 14" node_number="875"><div title="valid: False, node: 876, tag: div, level: 15" node_number="876">Juan Manuel Falc&#243;n-P&#233;rez</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 877, tag: div, level: 13" node_number="877"> Cancers <b class="valid" valid="valid" title="valid: True, node: 878, tag: b, level: 14" node_number="878">2021</b>, 13(24), 6216; https://doi.org/10.3390/cancers13246216 - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 879, tag: div, level: 13" node_number="879"> Abstract <div class="valid" valid="valid" title="valid: True, node: 880, tag: div, level: 14" node_number="880"> Background: Colorectal cancer (CRC), a major health concern, is developed depending on environmental, genetic and microbial factors. The microbiome and metabolome have been analyzed to study their role in CRC. However, the interplay of host genetics with those layers in CRC remains unclear. [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 881, tag: div, level: 14" node_number="881"> Background: Colorectal cancer (CRC), a major health concern, is developed depending on environmental, genetic and microbial factors. The microbiome and metabolome have been analyzed to study their role in CRC. However, the interplay of host genetics with those layers in CRC remains unclear. Methods: 120 individuals were sequenced and association analyses were carried out for adenoma and CRC risk, and for selected components of the microbiome and metabolome. The epistasis between genes located in cholesterol pathways was analyzed; modifiable risk factors were studied using Mendelian randomization; and the three omic layers were used to integrate their data and to build risk prediction models. Results: We detected genetic variants that were associated to components of metabolome or microbiome and adenoma or CRC risk (e.g., in <i title="valid: False, node: 882, tag: i, level: 15" node_number="882">LINC01605</i>, <i title="valid: False, node: 883, tag: i, level: 15" node_number="883">PROKR2</i> and <i title="valid: False, node: 884, tag: i, level: 15" node_number="884">CCSER1</i> genes). In addition, we found interactions between genes of cholesterol metabolism, and HDL cholesterol levels affected adenoma (<i title="valid: False, node: 885, tag: i, level: 15" node_number="885">p</i> = 0.0448) and CRC (<i title="valid: False, node: 886, tag: i, level: 15" node_number="886">p</i> = 0.0148) risk. The combination of the three omic layers to build risk prediction models reached high AUC values (&gt;0.91). Conclusions: The use of the three omic layers allowed for the finding of biological mechanisms related to the development of adenoma and CRC, and each layer provided complementary information to build risk prediction models. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 887, tag: div, level: 13" node_number="887"> (This article belongs to the Special Issue Recent Advances in Colorectal Cancer Diagnostics and Treatments) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 888, tag: div, level: 13" node_number="888"><div class="valid" valid="valid" title="valid: True, node: 889, tag: div, level: 14" node_number="889"><div title="valid: False, node: 890, tag: div, level: 15" node_number="890"><p title="valid: False, node: 891, tag: p, level: 16" node_number="891">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 892, tag: div, level: 10" node_number="892"> <div class="valid" valid="valid" title="valid: True, node: 893, tag: div, level: 11" node_number="893"> <div class="valid" valid="valid" title="valid: True, node: 894, tag: div, level: 12" node_number="894"> <div class="valid" valid="valid" title="valid: True, node: 895, tag: div, level: 13" node_number="895"> <a class="valid" valid="valid" title="valid: True, node: 896, tag: a, level: 14" node_number="896"> <i title="valid: False, node: 897, tag: i, level: 15" node_number="897">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 898, tag: div, level: 14" node_number="898"> Supplementary material: Supplementary File 1 (ZIP, 3070 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 899, tag: div, level: 13" node_number="899"> <a class="valid" valid="valid" title="valid: True, node: 900, tag: a, level: 14" node_number="900"> <i title="valid: False, node: 901, tag: i, level: 15" node_number="901">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 902, tag: div, level: 13" node_number="902"> <a class="valid" valid="valid" title="valid: True, node: 903, tag: a, level: 14" node_number="903"> <i title="valid: False, node: 904, tag: i, level: 15" node_number="904">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 905, tag: div, level: 14" node_number="905"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 906, tag: div, level: 13" node_number="906">Open AccessArticle</div> Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells <div class="valid" valid="valid" title="valid: True, node: 907, tag: div, level: 13" node_number="907"> by <span class="valid" valid="valid" title="valid: True, node: 908, tag: span, level: 14" node_number="908"><div title="valid: False, node: 909, tag: div, level: 15" node_number="909">David King</div>, </span><span class="valid" valid="valid" title="valid: True, node: 910, tag: span, level: 14" node_number="910"><div title="valid: False, node: 911, tag: div, level: 15" node_number="911">Harriet E. D. Southgate</div>, </span><span class="valid" valid="valid" title="valid: True, node: 912, tag: span, level: 14" node_number="912"><div title="valid: False, node: 913, tag: div, level: 15" node_number="913">Saskia Roetschke</div>, </span><span class="valid" valid="valid" title="valid: True, node: 914, tag: span, level: 14" node_number="914"><div title="valid: False, node: 915, tag: div, level: 15" node_number="915">Polly Gravells</div>, </span><span class="valid" valid="valid" title="valid: True, node: 916, tag: span, level: 14" node_number="916"><div title="valid: False, node: 917, tag: div, level: 15" node_number="917">Leona Fields</div>, </span><span class="valid" valid="valid" title="valid: True, node: 918, tag: span, level: 14" node_number="918"><div title="valid: False, node: 919, tag: div, level: 15" node_number="919">Jessica B. Watson</div>, </span><span class="valid" valid="valid" title="valid: True, node: 920, tag: span, level: 14" node_number="920"><div title="valid: False, node: 921, tag: div, level: 15" node_number="921">Lindi Chen</div>, </span><span class="valid" valid="valid" title="valid: True, node: 922, tag: span, level: 14" node_number="922"><div title="valid: False, node: 923, tag: div, level: 15" node_number="923">Devon Chapman</div>, </span><span class="valid" valid="valid" title="valid: True, node: 924, tag: span, level: 14" node_number="924"><div title="valid: False, node: 925, tag: div, level: 15" node_number="925">Daniel Harrison</div>, </span><span class="valid" valid="valid" title="valid: True, node: 926, tag: span, level: 14" node_number="926"><div title="valid: False, node: 927, tag: div, level: 15" node_number="927">Daniel Yeomanson</div>, </span><span class="valid" valid="valid" title="valid: True, node: 928, tag: span, level: 14" node_number="928"><div title="valid: False, node: 929, tag: div, level: 15" node_number="929">Nicola J. Curtin</div>, </span><span class="valid" valid="valid" title="valid: True, node: 930, tag: span, level: 14" node_number="930"><div title="valid: False, node: 931, tag: div, level: 15" node_number="931">Deborah A. Tweddle</div> and </span><span class="valid" valid="valid" title="valid: True, node: 932, tag: span, level: 14" node_number="932"><div title="valid: False, node: 933, tag: div, level: 15" node_number="933">Helen E. Bryant</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 934, tag: div, level: 13" node_number="934"> Cancers <b class="valid" valid="valid" title="valid: True, node: 935, tag: b, level: 14" node_number="935">2021</b>, 13(24), 6215; https://doi.org/10.3390/cancers13246215 - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 936, tag: div, level: 13" node_number="936"> Abstract <div class="valid" valid="valid" title="valid: True, node: 937, tag: div, level: 14" node_number="937"> Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in pre-clinical models of high-risk NB. Amplification of the oncogene [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 938, tag: div, level: 14" node_number="938"> Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in pre-clinical models of high-risk NB. Amplification of the oncogene <i title="valid: False, node: 939, tag: i, level: 15" node_number="939">MYCN</i> always imparts high-risk disease and occurs in 25% of all NB. Here, we show that MYCN-induced replication stress directly increases sensitivity to the ATR inhibitors VE-821 and AZD6738. PARP inhibition with Olaparib also results in replication stress and ATR activation, and sensitises NB cells to ATR inhibition independently of <i title="valid: False, node: 940, tag: i, level: 15" node_number="940">MYCN</i> status, with synergistic levels of cell death seen in MYCN expressing ATR- and PARP-inhibited cells. Mechanistically, we demonstrate that ATR inhibition increases the number of persistent stalled and collapsed replication forks, exacerbating replication stress. It also abrogates S and G2 cell cycle checkpoints leading to death during mitosis in cells treated with an ATR inhibitor combined with PARP inhibition. In summary, increased replication stress through high MYCN expression, PARP inhibition or chemotherapeutic agents results in sensitivity to ATR inhibition. Our findings provide a mechanistic rationale for the inclusion of ATR and PARP inhibitors as a potential treatment strategy for high-risk NB. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 941, tag: div, level: 13" node_number="941"> (This article belongs to the Special Issue Targeted Therapies for Pediatric Solid Tumors) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 942, tag: div, level: 13" node_number="942"><div class="valid" valid="valid" title="valid: True, node: 943, tag: div, level: 14" node_number="943"><div title="valid: False, node: 944, tag: div, level: 15" node_number="944"><p title="valid: False, node: 945, tag: p, level: 16" node_number="945">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 946, tag: div, level: 10" node_number="946"> <div class="valid" valid="valid" title="valid: True, node: 947, tag: div, level: 11" node_number="947"> <div class="valid" valid="valid" title="valid: True, node: 948, tag: div, level: 12" node_number="948"> <div class="valid" valid="valid" title="valid: True, node: 949, tag: div, level: 13" node_number="949"> <a class="valid" valid="valid" title="valid: True, node: 950, tag: a, level: 14" node_number="950"> <i title="valid: False, node: 951, tag: i, level: 15" node_number="951">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 952, tag: div, level: 13" node_number="952"> <a class="valid" valid="valid" title="valid: True, node: 953, tag: a, level: 14" node_number="953"> <i title="valid: False, node: 954, tag: i, level: 15" node_number="954">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 955, tag: div, level: 14" node_number="955"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 956, tag: div, level: 13" node_number="956">Open AccessFeature PaperReview</div> The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective <div class="valid" valid="valid" title="valid: True, node: 957, tag: div, level: 13" node_number="957"> by <span class="valid" valid="valid" title="valid: True, node: 958, tag: span, level: 14" node_number="958"><div title="valid: False, node: 959, tag: div, level: 15" node_number="959">Yi Xiao</div> and </span><span class="valid" valid="valid" title="valid: True, node: 960, tag: span, level: 14" node_number="960"><div title="valid: False, node: 961, tag: div, level: 15" node_number="961">Jixin Dong</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 962, tag: div, level: 13" node_number="962"> Cancers <b class="valid" valid="valid" title="valid: True, node: 963, tag: b, level: 14" node_number="963">2021</b>, 13(24), 6214; https://doi.org/10.3390/cancers13246214 - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 964, tag: div, level: 13" node_number="964"> Abstract <div class="valid" valid="valid" title="valid: True, node: 965, tag: div, level: 14" node_number="965"> Cell cycle progression is an elaborate process that requires stringent control for normal cellular function. Defects in cell cycle control, however, contribute to genomic instability and have become a characteristic phenomenon in cancers. Over the years, advancement in the understanding of disrupted cell [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 966, tag: div, level: 14" node_number="966"> Cell cycle progression is an elaborate process that requires stringent control for normal cellular function. Defects in cell cycle control, however, contribute to genomic instability and have become a characteristic phenomenon in cancers. Over the years, advancement in the understanding of disrupted cell cycle regulation in tumors has led to the development of powerful anti-cancer drugs. Therefore, an in-depth exploration of cell cycle dysregulation in cancers could provide therapeutic avenues for cancer treatment. The Hippo pathway is an evolutionarily conserved regulator network that controls organ size, and its dysregulation is implicated in various types of cancers. Although the role of the Hippo pathway in oncogenesis has been widely investigated, its role in cell cycle regulation has not been comprehensively scrutinized. Here, we specifically focus on delineating the involvement of the Hippo pathway in cell cycle regulation. To that end, we first compare the structural as well as functional conservation of the core Hippo pathway in yeasts, flies, and mammals. Then, we detail the multi-faceted aspects in which the core components of the mammalian Hippo pathway and their regulators affect the cell cycle, particularly with regard to the regulation of E2F activity, the G1 tetraploidy checkpoint, DNA synthesis, DNA damage checkpoint, centrosome dynamics, and mitosis. Finally, we briefly discuss how a collective understanding of cell cycle regulation and the Hippo pathway could be weaponized in combating cancer. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 967, tag: div, level: 13" node_number="967"> (This article belongs to the Special Issue Hippo Signaling Pathway in Cancers) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 968, tag: div, level: 13" node_number="968"><div class="valid" valid="valid" title="valid: True, node: 969, tag: div, level: 14" node_number="969"><div title="valid: False, node: 970, tag: div, level: 15" node_number="970"><p title="valid: False, node: 971, tag: p, level: 16" node_number="971">Figure 1</p></div></div></div> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 972, tag: div, level: 9" node_number="972"> More Articles... </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 973, tag: div, level: 6" node_number="973"> <div class="valid" valid="valid" title="valid: True, node: 974, tag: div, level: 7" node_number="974"> <div class="valid" valid="valid" title="valid: True, node: 975, tag: div, level: 8" node_number="975"> <div class="valid" valid="valid" title="valid: True, node: 976, tag: div, level: 9" node_number="976"> <a class="valid" valid="valid" title="valid: True, node: 977, tag: a, level: 10" node_number="977"> Submit to <i class="valid" valid="valid" title="valid: True, node: 978, tag: i, level: 11" node_number="978">Cancers</i> </a> Review for Cancers <div class="valid" valid="valid" title="valid: True, node: 979, tag: div, level: 10" node_number="979"> Share </div> </div> <div class="valid" valid="valid" title="valid: True, node: 980, tag: div, level: 9" node_number="980"> <h2 class="valid" valid="valid" title="valid: True, node: 981, tag: h2, level: 10" node_number="981">Journal Menu</h2> &#9658; &#9660; Journal Menu <ul class="valid" valid="valid" title="valid: True, node: 982, tag: ul, level: 10" node_number="982"> <li class="valid" valid="valid" title="valid: True, node: 983, tag: li, level: 11" node_number="983"> <ul class="valid" valid="valid" title="valid: True, node: 984, tag: ul, level: 12" node_number="984"> <li class="valid" valid="valid" title="valid: True, node: 985, tag: li, level: 13" node_number="985"> Cancers Home </li> <li class="valid" valid="valid" title="valid: True, node: 986, tag: li, level: 13" node_number="986"> Aims Scope </li> <li class="valid" valid="valid" title="valid: True, node: 987, tag: li, level: 13" node_number="987"> Editorial Board </li> <li class="valid" valid="valid" title="valid: True, node: 988, tag: li, level: 13" node_number="988"> Reviewer Board </li> <li class="valid" valid="valid" title="valid: True, node: 989, tag: li, level: 13" node_number="989"> Topical Advisory Panel </li> <li class="valid" valid="valid" title="valid: True, node: 990, tag: li, level: 13" node_number="990"> Instructions for Authors </li> <li class="valid" valid="valid" title="valid: True, node: 991, tag: li, level: 13" node_number="991"> Special Issues </li> <li class="valid" valid="valid" title="valid: True, node: 992, tag: li, level: 13" node_number="992"> Sections Collections </li> <li class="valid" valid="valid" title="valid: True, node: 993, tag: li, level: 13" node_number="993"> Article Processing Charge </li> <li class="valid" valid="valid" title="valid: True, node: 994, tag: li, level: 13" node_number="994"> Indexing Archiving </li> <li class="valid" valid="valid" title="valid: True, node: 995, tag: li, level: 13" node_number="995"> Editor's Choice Articles </li> <li class="valid" valid="valid" title="valid: True, node: 996, tag: li, level: 13" node_number="996"> Most Cited Viewed </li> <li class="valid" valid="valid" title="valid: True, node: 997, tag: li, level: 13" node_number="997"> Journal Statistics </li> <li class="valid" valid="valid" title="valid: True, node: 998, tag: li, level: 13" node_number="998"> Journal History </li> <li class="valid" valid="valid" title="valid: True, node: 999, tag: li, level: 13" node_number="999"> Journal Awards </li> <li class="valid" valid="valid" title="valid: True, node: 1000, tag: li, level: 13" node_number="1000"> Society Collaborations </li> <li class="valid" valid="valid" title="valid: True, node: 1001, tag: li, level: 13" node_number="1001"> Conferences </li> <li class="valid" valid="valid" title="valid: True, node: 1002, tag: li, level: 13" node_number="1002"> Editorial Office </li> </ul> </li> </ul> </div> <h2 class="valid" valid="valid" title="valid: True, node: 1003, tag: h2, level: 9" node_number="1003">Journal Browser</h2> &#9658; &#9660; Journal Browser <div class="valid" valid="valid" title="valid: True, node: 1004, tag: div, level: 9" node_number="1004"> <div class="valid" valid="valid" title="valid: True, node: 1005, tag: div, level: 10" node_number="1005"> <ul class="valid" valid="valid" title="valid: True, node: 1006, tag: ul, level: 11" node_number="1006"> <li class="valid" valid="valid" title="valid: True, node: 1007, tag: li, level: 12" node_number="1007"> <a class="valid" valid="valid" title="valid: True, node: 1008, tag: a, level: 13" node_number="1008"> <i class="valid" valid="valid" title="valid: True, node: 1009, tag: i, level: 14" node_number="1009"> arrow_forward_ios </i> Forthcoming issue </a> <a class="valid" valid="valid" title="valid: True, node: 1010, tag: a, level: 13" node_number="1010"> <i class="valid" valid="valid" title="valid: True, node: 1011, tag: i, level: 14" node_number="1011"> arrow_forward_ios </i> Current issue </a> </li> <div class="valid" valid="valid" title="valid: True, node: 1012, tag: div, level: 12" node_number="1012"> <div class="valid" valid="valid" title="valid: True, node: 1013, tag: div, level: 13" node_number="1013"> <div class="valid" valid="valid" title="valid: True, node: 1014, tag: div, level: 14" node_number="1014"> <li title="valid: False, node: 1015, tag: li, level: 15" node_number="1015"> Vol.&#160;13&#160;(2021) </li> <li title="valid: False, node: 1016, tag: li, level: 15" node_number="1016"> Vol.&#160;12&#160;(2020) </li> <li title="valid: False, node: 1017, tag: li, level: 15" node_number="1017"> Vol.&#160;11&#160;(2019) </li> <li title="valid: False, node: 1018, tag: li, level: 15" node_number="1018"> Vol.&#160;10&#160;(2018) </li> <li title="valid: False, node: 1019, tag: li, level: 15" node_number="1019"> Vol.&#160;9&#160;(2017) </li> <li title="valid: False, node: 1020, tag: li, level: 15" node_number="1020"> Vol.&#160;8&#160;(2016) </li> <li title="valid: False, node: 1021, tag: li, level: 15" node_number="1021"> Vol.&#160;7&#160;(2015) </li> <li title="valid: False, node: 1022, tag: li, level: 15" node_number="1022"> Vol.&#160;6&#160;(2014) </li> <li title="valid: False, node: 1023, tag: li, level: 15" node_number="1023"> Vol.&#160;5&#160;(2013) </li> <li title="valid: False, node: 1024, tag: li, level: 15" node_number="1024"> Vol.&#160;4&#160;(2012) </li> <li title="valid: False, node: 1025, tag: li, level: 15" node_number="1025"> Vol.&#160;3&#160;(2011) </li> <li title="valid: False, node: 1026, tag: li, level: 15" node_number="1026"> Vol.&#160;2&#160;(2010) </li> <li title="valid: False, node: 1027, tag: li, level: 15" node_number="1027"> Vol.&#160;1&#160;(2009) </li> </div> </div> </div> </ul> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1028, tag: div, level: 7" node_number="1028"> <div class="valid" valid="valid" title="valid: True, node: 1029, tag: div, level: 8" node_number="1029"> <h2 class="valid" valid="valid" title="valid: True, node: 1030, tag: h2, level: 9" node_number="1030">Highly Accessed Articles</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1031, tag: div, level: 8" node_number="1031"> <div class="valid" valid="valid" title="valid: True, node: 1032, tag: div, level: 9" node_number="1032"> View More... </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1033, tag: div, level: 7" node_number="1033"> <div class="valid" valid="valid" title="valid: True, node: 1034, tag: div, level: 8" node_number="1034"> <h2 class="valid" valid="valid" title="valid: True, node: 1035, tag: h2, level: 9" node_number="1035">Latest Books</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1036, tag: div, level: 8" node_number="1036"> <div class="valid" valid="valid" title="valid: True, node: 1037, tag: div, level: 9" node_number="1037"> More Open Access Books... </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1038, tag: div, level: 6" node_number="1038"> <div class="valid" valid="valid" title="valid: True, node: 1039, tag: div, level: 7" node_number="1039"> <div class="valid" valid="valid" title="valid: True, node: 1040, tag: div, level: 8" node_number="1040"> <h2 class="valid" valid="valid" title="valid: True, node: 1041, tag: h2, level: 9" node_number="1041">E-Mail Alert</h2> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1042, tag: div, level: 7" node_number="1042"> <div class="valid" valid="valid" title="valid: True, node: 1043, tag: div, level: 8" node_number="1043"> <h2 class="valid" valid="valid" title="valid: True, node: 1044, tag: h2, level: 9" node_number="1044">News</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1045, tag: div, level: 8" node_number="1045"> <div class="valid" valid="valid" title="valid: True, node: 1046, tag: div, level: 9" node_number="1046"> 22 November 2021 720 MDPI Editorial Board Members Receiving "2021 Highly Cited Researchers" Distinction </div> <div class="valid" valid="valid" title="valid: True, node: 1047, tag: div, level: 9" node_number="1047"> 16 November 2021 Topical Advisory Panel Established to Support Editorial Board </div> <div class="valid" valid="valid" title="valid: True, node: 1048, tag: div, level: 9" node_number="1048"> 25 October 2021 Open Access Week 2021 | It Matters How We Open Knowledge: Building Structural Equity, 25&#8211;31 October </div> <div class="valid" valid="valid" title="valid: True, node: 1049, tag: div, level: 9" node_number="1049"> More News Announcements... </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1050, tag: div, level: 7" node_number="1050"> <div class="valid" valid="valid" title="valid: True, node: 1051, tag: div, level: 8" node_number="1051"> <h2 class="valid" valid="valid" title="valid: True, node: 1052, tag: h2, level: 9" node_number="1052">Topics</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1053, tag: div, level: 8" node_number="1053"> <div class="valid" valid="valid" title="valid: True, node: 1054, tag: div, level: 9" node_number="1054"><div class="valid" valid="valid" title="valid: True, node: 1055, tag: div, level: 10" node_number="1055"> Topic in Biomedicines, Pharmaceutics, Pharmaceuticals, Cancers, Vaccines</div> Animal Model in Biomedical Research Editor-in-Chief: Marc EkkerDeadline: 31 December 2021</div> <div class="valid" valid="valid" title="valid: True, node: 1056, tag: div, level: 9" node_number="1056"><div class="valid" valid="valid" title="valid: True, node: 1057, tag: div, level: 10" node_number="1057"> Topic in Biology, Cancers</div> Application of Big Medical Data in Precision Medicine Editors-in-Chief: Yi Zhao, Jinpu Yu, Haifeng Zhang, Min Hu, Jincheng GuoDeadline: 31 March 2022</div> <div class="valid" valid="valid" title="valid: True, node: 1058, tag: div, level: 9" node_number="1058"><div class="valid" valid="valid" title="valid: True, node: 1059, tag: div, level: 10" node_number="1059"> Topic in Biomolecules, Cancers, Cells, Current Oncology</div> Advances in Ovarian Cancer Research: From Biology to Therapeutics Editor-in-Chief: Christina M. AnnunziataDeadline: 31 May 2022</div> <div class="valid" valid="valid" title="valid: True, node: 1060, tag: div, level: 9" node_number="1060"><div class="valid" valid="valid" title="valid: True, node: 1061, tag: div, level: 10" node_number="1061"> Topic in Biomolecules, Cancers, Cells, Current Oncology, Onco</div> Adaptation Mechanisms in Therapy-Resistant Breast Cancer Deadline: 31 July 2022</div> <div class="valid" valid="valid" title="valid: True, node: 1062, tag: div, level: 9" node_number="1062"> More Topics </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1063, tag: div, level: 7" node_number="1063"> <div class="valid" valid="valid" title="valid: True, node: 1064, tag: div, level: 8" node_number="1064"> <h2 class="valid" valid="valid" title="valid: True, node: 1065, tag: h2, level: 9" node_number="1065">Conferences</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1066, tag: div, level: 8" node_number="1066"> <div class="valid" valid="valid" title="valid: True, node: 1067, tag: div, level: 9" node_number="1067"> Announce Your Conference </div> <div class="valid" valid="valid" title="valid: True, node: 1068, tag: div, level: 9" node_number="1068"> 14&#8211;16 February 2022 IECC 2022: Tumor Microenvironment Heterogeneity in Cancer Progression: Challenge or Opportunity</div> <div class="valid" valid="valid" title="valid: True, node: 1069, tag: div, level: 9" node_number="1069"> More Conferences... </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1070, tag: div, level: 7" node_number="1070"> <div class="valid" valid="valid" title="valid: True, node: 1071, tag: div, level: 8" node_number="1071"> <h2 class="valid" valid="valid" title="valid: True, node: 1072, tag: h2, level: 9" node_number="1072">Special Issues</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1073, tag: div, level: 8" node_number="1073"> <div class="valid" valid="valid" title="valid: True, node: 1074, tag: div, level: 9" node_number="1074"> Edit a Special Issue </div> <div class="valid" valid="valid" title="valid: True, node: 1075, tag: div, level: 9" node_number="1075"><div class="valid" valid="valid" title="valid: True, node: 1076, tag: div, level: 10" node_number="1076"> Special Issue in Cancers</div> Nuclear Receptors and Cancer Guest Editors: Zeynep Madak-Erdogan, Matthew SikoraDeadline: 15 December 2021</div> <div class="valid" valid="valid" title="valid: True, node: 1077, tag: div, level: 9" node_number="1077"><div class="valid" valid="valid" title="valid: True, node: 1078, tag: div, level: 10" node_number="1078"> Special Issue in Cancers</div> Perioperative Interventions and Oncological Outcome in Surgical Cancer Patients Guest Editor: Donal J BuggyDeadline: 31 December 2021</div> <div class="valid" valid="valid" title="valid: True, node: 1079, tag: div, level: 9" node_number="1079"><div class="valid" valid="valid" title="valid: True, node: 1080, tag: div, level: 10" node_number="1080"> Special Issue in Cancers</div> Gammopathies of Certain Significance: Managing MGUS and Smoldering Myeloma Guest Editors: Maximilian Merz, Hartmut GoldschmidtDeadline: 1 January 2022</div> <div class="valid" valid="valid" title="valid: True, node: 1081, tag: div, level: 9" node_number="1081"><div class="valid" valid="valid" title="valid: True, node: 1082, tag: div, level: 10" node_number="1082"> Special Issue in Cancers</div> Nanoparticle-Based Combination Therapy and Diagnosis for Cancer Guest Editors: Elena Reddi, Francesca MoretDeadline: 15 January 2022</div> <div class="valid" valid="valid" title="valid: True, node: 1083, tag: div, level: 9" node_number="1083"> More Special Issues </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1084, tag: div, level: 7" node_number="1084"> <div class="valid" valid="valid" title="valid: True, node: 1085, tag: div, level: 8" node_number="1085"> <h2 class="valid" valid="valid" title="valid: True, node: 1086, tag: h2, level: 9" node_number="1086">Topical Collections</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1087, tag: div, level: 8" node_number="1087"> <div class="valid" valid="valid" title="valid: True, node: 1088, tag: div, level: 9" node_number="1088"><div class="valid" valid="valid" title="valid: True, node: 1089, tag: div, level: 10" node_number="1089"> Topical Collection in Cancers</div> Urological Cancer Collection Editor: Jos&#233; I. L&#243;pez</div> <div class="valid" valid="valid" title="valid: True, node: 1090, tag: div, level: 9" node_number="1090"><div class="valid" valid="valid" title="valid: True, node: 1091, tag: div, level: 10" node_number="1091"> Topical Collection in Cancers</div> Drug Resistance and Novel Therapies in Cancers Collection Editor: Zhixiang Wang</div> <div class="valid" valid="valid" title="valid: True, node: 1092, tag: div, level: 9" node_number="1092"><div class="valid" valid="valid" title="valid: True, node: 1093, tag: div, level: 10" node_number="1093"> Topical Collection in Cancers</div> The Role of Non-coding RNA in Cancer Collection Editor: Lyndsay Rhodes</div> <div class="valid" valid="valid" title="valid: True, node: 1094, tag: div, level: 9" node_number="1094"><div class="valid" valid="valid" title="valid: True, node: 1095, tag: div, level: 10" node_number="1095"> Topical Collection in Cancers</div> Deciphering the Crosstalk between Tumor Cells and Their Microenvironment: From Molecular Aspects to Therapeutic Implications Collection Editors: Patrizia Limonta, Fabrizio Fontana</div> <div class="valid" valid="valid" title="valid: True, node: 1096, tag: div, level: 9" node_number="1096"> More Topical Collections </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1097, tag: div, level: 7" node_number="1097"> <div class="valid" valid="valid" title="valid: True, node: 1098, tag: div, level: 8" node_number="1098"> <h2 class="valid" valid="valid" title="valid: True, node: 1099, tag: h2, level: 9" node_number="1099">Jobs in Research</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1100, tag: div, level: 8" node_number="1100"> <div class="valid" valid="valid" title="valid: True, node: 1101, tag: div, level: 9" node_number="1101"> Post New Job Opening </div> </div> </div> </div> </div> </div> </section> <div class="valid" valid="valid" title="valid: True, node: 1102, tag: div, level: 3" node_number="1102"> <div class="valid" valid="valid" title="valid: True, node: 1103, tag: div, level: 4" node_number="1103"> Cancers, EISSN 2072-6694, Published by MDPI <span class="valid" valid="valid" title="valid: True, node: 1104, tag: span, level: 5" node_number="1104"> Disclaimer <div class="valid" valid="valid" title="valid: True, node: 1105, tag: div, level: 6" node_number="1105"> The statements, opinions and data contained in the journal Cancers are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. </div> </span> <div class="valid" valid="valid" title="valid: True, node: 1106, tag: div, level: 5" node_number="1106"> RSS Content Alert </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1107, tag: div, level: 4" node_number="1107"> <div class="valid" valid="valid" title="valid: True, node: 1108, tag: div, level: 5" node_number="1108"> <h3 class="valid" valid="valid" title="valid: True, node: 1109, tag: h3, level: 6" node_number="1109"> Further Information </h3> <a class="valid" valid="valid" title="valid: True, node: 1110, tag: a, level: 6" node_number="1110"> Article Processing Charges </a> <a class="valid" valid="valid" title="valid: True, node: 1111, tag: a, level: 6" node_number="1111"> Pay an Invoice </a> <a class="valid" valid="valid" title="valid: True, node: 1112, tag: a, level: 6" node_number="1112"> Open Access Policy </a> <a class="valid" valid="valid" title="valid: True, node: 1113, tag: a, level: 6" node_number="1113"> Contact MDPI </a> <a class="valid" valid="valid" title="valid: True, node: 1114, tag: a, level: 6" node_number="1114"> Jobs at MDPI </a> </div> <div class="valid" valid="valid" title="valid: True, node: 1115, tag: div, level: 5" node_number="1115"> <h3 class="valid" valid="valid" title="valid: True, node: 1116, tag: h3, level: 6" node_number="1116"> Guidelines </h3> <a class="valid" valid="valid" title="valid: True, node: 1117, tag: a, level: 6" node_number="1117"> For Authors </a> <a class="valid" valid="valid" title="valid: True, node: 1118, tag: a, level: 6" node_number="1118"> For Reviewers </a> <a class="valid" valid="valid" title="valid: True, node: 1119, tag: a, level: 6" node_number="1119"> For Editors </a> <a class="valid" valid="valid" title="valid: True, node: 1120, tag: a, level: 6" node_number="1120"> For Librarians </a> <a class="valid" valid="valid" title="valid: True, node: 1121, tag: a, level: 6" node_number="1121"> For Publishers </a> <a class="valid" valid="valid" title="valid: True, node: 1122, tag: a, level: 6" node_number="1122"> For Societies </a> </div> <div class="valid" valid="valid" title="valid: True, node: 1123, tag: div, level: 5" node_number="1123"> <h3 class="valid" valid="valid" title="valid: True, node: 1124, tag: h3, level: 6" node_number="1124"> MDPI Initiatives </h3> <a class="valid" valid="valid" title="valid: True, node: 1125, tag: a, level: 6" node_number="1125"> Sciforum </a> <a class="valid" valid="valid" title="valid: True, node: 1126, tag: a, level: 6" node_number="1126"> MDPI Books </a> <a class="valid" valid="valid" title="valid: True, node: 1127, tag: a, level: 6" node_number="1127"> Preprints </a> <a class="valid" valid="valid" title="valid: True, node: 1128, tag: a, level: 6" node_number="1128"> Scilit </a> <a class="valid" valid="valid" title="valid: True, node: 1129, tag: a, level: 6" node_number="1129"> SciProfiles </a> <a class="valid" valid="valid" title="valid: True, node: 1130, tag: a, level: 6" node_number="1130"> Encyclopedia </a> <a class="valid" valid="valid" title="valid: True, node: 1131, tag: a, level: 6" node_number="1131"> JAMS </a> <a class="valid" valid="valid" title="valid: True, node: 1132, tag: a, level: 6" node_number="1132"> Proceedings Series </a> </div> <div class="valid" valid="valid" title="valid: True, node: 1133, tag: div, level: 5" node_number="1133"> <h3 class="valid" valid="valid" title="valid: True, node: 1134, tag: h3, level: 6" node_number="1134"> Follow MDPI </h3> <a class="valid" valid="valid" title="valid: True, node: 1135, tag: a, level: 6" node_number="1135"> LinkedIn </a> <a class="valid" valid="valid" title="valid: True, node: 1136, tag: a, level: 6" node_number="1136"> Facebook </a> <a class="valid" valid="valid" title="valid: True, node: 1137, tag: a, level: 6" node_number="1137"> Twitter </a> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1138, tag: div, level: 4" node_number="1138"> <div class="valid" valid="valid" title="valid: True, node: 1139, tag: div, level: 5" node_number="1139"> <div class="valid" valid="valid" title="valid: True, node: 1140, tag: div, level: 6" node_number="1140"> &#169; 1996-2021 MDPI (Basel, Switzerland) unless otherwise stated </div> <div class="valid" valid="valid" title="valid: True, node: 1141, tag: div, level: 6" node_number="1141"> <a class="valid" valid="valid" title="valid: True, node: 1142, tag: a, level: 7" node_number="1142"> Disclaimer </a> <div class="valid" valid="valid" title="valid: True, node: 1143, tag: div, level: 7" node_number="1143"> The statements, opinions and data contained in the journals are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. </div> <a class="valid" valid="valid" title="valid: True, node: 1144, tag: a, level: 7" node_number="1144"> Terms and Conditions </a> <a class="valid" valid="valid" title="valid: True, node: 1145, tag: a, level: 7" node_number="1145"> Privacy Policy </a> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1146, tag: div, level: 3" node_number="1146"> <div class="valid" valid="valid" title="valid: True, node: 1147, tag: div, level: 4" node_number="1147"> We use cookies on our website to ensure you get the best experience. Read more about our cookies <a class="valid" valid="valid" title="valid: True, node: 1148, tag: a, level: 5" node_number="1148">here</a>. </div> <div class="valid" valid="valid" title="valid: True, node: 1149, tag: div, level: 4" node_number="1149"> <a class="valid" valid="valid" title="valid: True, node: 1150, tag: a, level: 5" node_number="1150">Accept</a> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1151, tag: div, level: 3" node_number="1151"> <div class="valid" valid="valid" title="valid: True, node: 1152, tag: div, level: 4" node_number="1152"> We have just recently launched a new version of our website. Help us to further improve by taking part in this short 5 minute survey here. here. </div> <div class="valid" valid="valid" title="valid: True, node: 1153, tag: div, level: 4" node_number="1153"> <a class="valid" valid="valid" title="valid: True, node: 1154, tag: a, level: 5" node_number="1154">Never show this again</a> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1155, tag: div, level: 2" node_number="1155"> <div class="valid" valid="valid" title="valid: True, node: 1156, tag: div, level: 3" node_number="1156"> <div class="valid" valid="valid" title="valid: True, node: 1157, tag: div, level: 4" node_number="1157"> <h2 class="valid" valid="valid" title="valid: True, node: 1158, tag: h2, level: 5" node_number="1158">Share Link</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1159, tag: div, level: 4" node_number="1159"> <a class="valid" valid="valid" title="valid: True, node: 1160, tag: a, level: 5" node_number="1160">Copy</a> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 1161, tag: a, level: 3" node_number="1161"> <i class="valid" valid="valid" title="valid: True, node: 1162, tag: i, level: 4" node_number="1162">clear</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 1163, tag: div, level: 2" node_number="1163"> <div class="valid" valid="valid" title="valid: True, node: 1164, tag: div, level: 3" node_number="1164"> <div class="valid" valid="valid" title="valid: True, node: 1165, tag: div, level: 4" node_number="1165"> <h2 class="valid" valid="valid" title="valid: True, node: 1166, tag: h2, level: 5" node_number="1166">Share</h2> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 1167, tag: a, level: 3" node_number="1167"> <i class="valid" valid="valid" title="valid: True, node: 1168, tag: i, level: 4" node_number="1168">clear</i> </a> </div> <a class="valid" valid="valid" title="valid: True, node: 1169, tag: a, level: 2" node_number="1169">Back to TopTop</a> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>